Ian O Ellis

List of Publications by Year in Descending Order

708 papers	50,930 citations	101 h-index	201 g-index
742 ext. papers	58,610 ext. citations	6.5 avg, IF	7.29 L-index

#	Paper	IF	Citations
708	Epigenome erosion and SOX10 drive neural crest phenotypic mimicry in triple-negative breast cancer.. *Npj Breast Cancer*, **2022**, 8, 57	7.8	1
707	Digital pathology: the effect of experience on visual search behavior.. *Journal of Medical Imaging*, **2022**, 9, 035501	2.6	0
706	Aurora Kinase A Is an Independent Predictor of Invasive Recurrence in Breast Ductal Carcinoma in situ.. *Pathobiology*, **2022**, 1-11	3.6	1
705	Receptor, Signal, Nucleus, Action: Signals That Pass through Akt on the Road to Head and Neck Cancer Cell Migration. *Cancers*, **2022**, 14, 2606	6.6	
704	Triple-Negative Breast Cancer Histological Subtypes with a Favourable Prognosis. *Cancers*, **2021**, 13,	6.6	6
703	POSNOC-POsitive Sentinel NOde: adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy: a randomised controlled trial of axillary treatment in women with early-stage breast cancer who have metastases in one or two sentinel nodes. *BMJ Open*, **2021**, 11, e054365	3	4
702	Nuclear morphology in breast lesions: refining its assessment to improve diagnostic concordance. *Histopathology*, **2021**, 80, 515	7.3	2
701	Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patients undergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio 2.0, HER2 copy number . *British Journal of Cancer*, **2021**, 124, 1836-1842	8.7	2
700	PP1, PKA and DARPP-32 in breast cancer: A retrospective assessment of protein and mRNA expression. *Journal of Cellular and Molecular Medicine*, **2021**, 25, 5015-5024	5.6	1
699	Adenomyoepithelioma of the breast: a proposal for classification. *Histopathology*, **2021**, 79, 465-479	7.3	10
698	Diagnostic concordance of phyllodes tumour of the breast. *Histopathology*, **2021**, 79, 607-618	7.3	0
697	Is RAS the Link Between COVID-19 and Increased Stress in Head and Neck Cancer Patients?. *Frontiers in Cell and Developmental Biology*, **2021**, 9, 714999	5.7	2
696	SLC1A5 co-expression with TALDO1 associates with endocrine therapy failure in estrogen receptor-positive breast cancer. *Breast Cancer Research and Treatment*, **2021**, 189, 317-331	4.4	1
695	Grading of invasive breast carcinoma: the way forward. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2021**, 1	5.1	8
694	Comparison of machine learning algorithms for the prediction of five-year survival in oral squamous cell carcinoma. *Journal of Oral Pathology and Medicine*, **2021**, 50, 378-384	3.3	11
693	Metaplastic carcinomas of the breast without evidence of epithelial differentiation: a diagnostic approach for management. *Histopathology*, **2021**, 78, 759-771	7.3	3
692	Cancer and Stress: Does It Make a Difference to the Patient When These Two Challenges Collide?. *Cancers*, **2021**, 13,	6.6	7

691	The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer. *Nature Medicine*, **2021**, 27, 310-320	50.5	40
690	Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer. *Modern Pathology*, **2021**, 34, 1271-1281	9.8	12
689	Correlations of morphological features and surgical management with clinical outcome in a multicentre study of 241 phyllodes tumours of the breast. *Histopathology*, **2021**, 78, 871-881	7.3	2
688	DNA methylation landscapes of 1538 breast cancers reveal a replication-linked clock, epigenomic instability and cis-regulation. *Nature Communications*, **2021**, 12, 5406	17.4	6
687	Retrospective assessment of cyclin-dependent kinase 5 mRNA and protein expression and its association with patient survival in breast cancer. *Journal of Cellular and Molecular Medicine*, **2020**, 24, 6263-6271	5.6	4
686	A novel prognostic two-gene signature for triple negative breast cancer. *Modern Pathology*, **2020**, 33, 2208-2220	9.8	13
685	Histological clues to the diagnosis of metastasis to the breast from extramammary malignancies. *Histopathology*, **2020**, 77, 303-313	7.3	6
684	PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer. *BMC Cancer*, **2020**, 20, 425	4.8	5
683	Perineural invasion in oral squamous cell carcinoma: Incidence, prognostic impact and molecular insight. *Journal of Oral Pathology and Medicine*, **2020**, 49, 994-1003	3.3	4
682	Integrated Analysis of Key Differentially Expressed Genes Identifies DBN1 as a Predictive Marker of Response to Endocrine Therapy in Luminal Breast Cancer. *Cancers*, **2020**, 12,	6.6	3
681	The solute carrier SLC7A8 is a marker of favourable prognosis in ER-positive low proliferative invasive breast cancer. *Breast Cancer Research and Treatment*, **2020**, 181, 1-12	4.4	3
680	Cytoplasmic Cyclin E Is an Independent Marker of Aggressive Tumor Biology and Breast Cancer-Specific Mortality in Women over 70 Years of Age. *Cancers*, **2020**, 12,	6.6	2
679	Co-Expression Effect of SLC7A5/SLC3A2 to Predict Response to Endocrine Therapy in Oestrogen-Receptor-Positive Breast Cancer. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	12
678	Combined HER3-EGFR score in triple-negative breast cancer provides prognostic and predictive significance superior to individual biomarkers. *Scientific Reports*, **2020**, 10, 3009	4.9	11
677	The 2019 World Health Organization classification of tumours of the breast. *Histopathology*, **2020**, 77, 181-185	7.3	131
676	Annual mammographic screening to reduce breast cancer mortality in women from age 40 years: long-term follow-up of the UK Age RCT. *Health Technology Assessment*, **2020**, 24, 1-24	4.4	5
675	Breast Pathology. *Encyclopedia of Pathology*, **2020**, 185-195	0	0
674	Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival. *Breast Cancer Research and Treatment*, **2020**, 182, 267-282	4.4	12

#	Reference	IF	Cites
673	Immunohistochemical assessment of HRAS Q61R mutations in breast adenomyoepitheliomas. *Histopathology*, **2020**, 76, 865-874	7.3	13
672	Enhanced glutamine uptake influences composition of immune cell infiltrates in breast cancer. *British Journal of Cancer*, **2020**, 122, 94-101	8.7	13
671	Nerve growth factor-induced migration in oral and salivary gland tumour cells utilises the PI3K/Akt signalling pathway: Is there a link to perineural invasion?. *Journal of Oral Pathology and Medicine*, **2020**, 49, 227-234	3.3	8
670	Biology of Oestrogen-Receptor Positive Primary Breast Cancer in Older Women with Utilisation of Core Needle Biopsy Samples and Correlation with Clinical Outcome. *Cancers*, **2020**, 12,	6.6	2
669	Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets. *Breast Cancer Research*, **2020**, 22, 85	8.3	11
668	Effect of mammographic screening from age 40 years on breast cancer mortality (UK Age trial): final results of a randomised, controlled trial. *Lancet Oncology, The*, **2020**, 21, 1165-1172	21.7	47
667	Association of Sperm-Associated Antigen 5 and Treatment Response in Patients With Estrogen Receptor-Positive Breast Cancer. *JAMA Network Open*, **2020**, 3, e209486	10.4	2
666	The prognostic significance of wild-type isocitrate dehydrogenase 2 (IDH2) in breast cancer. *Breast Cancer Research and Treatment*, **2020**, 179, 79-90	4.4	8
665	Prognostic significance of cathepsin V (CTSV/CTSL2) in breast ductal carcinoma in situ. *Journal of Clinical Pathology*, **2020**, 73, 76-82	3.9	23
664	Activated zinc transporter ZIP7 as an indicator of anti-hormone resistance in breast cancer. *Metallomics*, **2019**, 11, 1579-1592	4.5	8
663	CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy. *Breast Cancer Research and Treatment*, **2019**, 178, 535-544	4.4	17
662	Retinoid X receptor gamma (RXRG) is an independent prognostic biomarker in ER-positive invasive breast cancer. *British Journal of Cancer*, **2019**, 121, 776-785	8.7	7
661	Assessment of and rearrangements in breast adenomyoepitheliomas. *Npj Breast Cancer*, **2019**, 5, 6	7.8	15
660	Liver Kinase B1-A Potential Therapeutic Target in Hormone-Sensitive Breast Cancer in Older Women. *Cancers*, **2019**, 11,	6.6	7
659	The combined expression of solute carriers is associated with a poor prognosis in highly proliferative ER+ breast cancer. *Breast Cancer Research and Treatment*, **2019**, 175, 27-38	4.4	14
658	Collagen (XI) alpha-1 chain is an independent prognostic factor in breast ductal carcinoma in situ. *Modern Pathology*, **2019**, 32, 1460-1472	9.8	13
657	Geometric characteristics of collagen have independent prognostic significance in breast ductal carcinoma in situ: an image analysis study. *Modern Pathology*, **2019**, 32, 1473-1485	9.8	6
656	Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL): an overview of presentation and pathogenesis and guidelines for pathological diagnosis and management. *Histopathology*, **2019**, 75, 787-796	7.3	26

655	A key genomic subtype associated with lymphovascular invasion in invasive breast cancer. *British Journal of Cancer*, **2019**, 120, 1129-1136	8.7	12
654	Combining clustering and classification ensembles: A novel pipeline to identify breast cancer profiles. *Artificial Intelligence in Medicine*, **2019**, 97, 27-37	7.4	18
653	The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ: a large study from a single institution. *British Journal of Cancer*, **2019**, 120, 1075-1082	8.7	15
652	Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups. *Nature*, **2019**, 567, 399-404	50.4	108
651	Utility of ankyrin 3 as a prognostic marker in androgen-receptor-positive breast cancer. *Breast Cancer Research and Treatment*, **2019**, 176, 63-73	4.4	4
650	The prognostic significance of lysosomal protective protein (cathepsin A) in breast ductal carcinoma in situ. *Histopathology*, **2019**, 74, 1025-1035	7.3	11
649	Behaviour and characteristics of low-grade ductal carcinoma in situ of the breast: literature review and single-centre retrospective series. *Histopathology*, **2019**, 74, 970-987	7.3	3
648	The role of PIP5K1⍺/pAKT and targeted inhibition of growth of subtypes of breast cancer using PIP5K1⍺ inhibitor. *Oncogene*, **2019**, 38, 375-389	9.2	12
647	Machine learning-based prediction of breast cancer growth rate in vivo. *British Journal of Cancer*, **2019**, 121, 497-504	8.7	2
646	Surgical management of ductal carcinoma in situ of the breast: A large retrospective study from a single institution. *Breast Journal*, **2019**, 25, 1143-1153	1.2	3
645	A whole slide image-based machine learning approach to predict ductal carcinoma in situ (DCIS) recurrence risk. *Breast Cancer Research*, **2019**, 21, 83	8.3	22
644	SHON expression predicts response and relapse risk of breast cancer patients after anthracycline-based combination chemotherapy or tamoxifen treatment. *British Journal of Cancer*, **2019**, 120, 728-745	8.7	2
643	The molecular mechanisms underlying reduced E-cadherin expression in invasive ductal carcinoma of the breast: high throughput analysis of large cohorts. *Modern Pathology*, **2019**, 32, 967-976	9.8	17
642	Dopamine and cAMP-regulated phosphoprotein 32 kDa (DARPP-32) and survival in breast cancer: a retrospective analysis of protein and mRNA expression. *Scientific Reports*, **2019**, 9, 16987	4.9	5
641	An End-to-End Deep Learning Histochemical Scoring System for Breast Cancer TMA. *IEEE Transactions on Medical Imaging*, **2019**, 38, 617-628	11.7	17
640	Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer. *Breast Cancer Research and Treatment*, **2019**, 174, 387-399	4.4	33
639	Connexin 43 is an independent predictor of patient outcome in breast cancer patients. *Breast Cancer Research and Treatment*, **2019**, 174, 93-102	4.4	20
638	Legumain is an independent predictor for invasive recurrence in breast ductal carcinoma in situ. *Modern Pathology*, **2019**, 32, 639-649	9.8	9

637	Glutamate dehydrogenase (GLUD1) expression in breast cancer. *Breast Cancer Research and Treatment*, **2019**, 174, 79-91	4.4	16
636	Expression of Lamin A/C in early-stage breast cancer and its prognostic value. *Breast Cancer Research and Treatment*, **2019**, 174, 661-668	4.4	25
635	Kinesin family member-18A (KIF18A) is a predictive biomarker of poor benefit from endocrine therapy in early ER+ breast cancer. *Breast Cancer Research and Treatment*, **2019**, 173, 93-102	4.4	12
634	Immune Infiltration in Invasive Lobular Breast Cancer. *Journal of the National Cancer Institute*, **2018**, 110, 768-776	9.7	55
633	Clinical and biological roles of Kelch-like family member 7 in breast cancer: a marker of poor prognosis. *Breast Cancer Research and Treatment*, **2018**, 170, 525-533	4.4	9
632	BQ323636.1, a Novel Splice Variant to 2, as a Predictor for Tamoxifen-Resistant Breast Cancer. *Clinical Cancer Research*, **2018**, 24, 3681-3691	12.9	12
631	Tumour Heterogeneity of Breast Cancer: From Morphology to Personalised Medicine. *Pathobiology*, **2018**, 85, 23-34	3.6	45
630	Targeting ataxia telangiectasia-mutated- and Rad3-related kinase (ATR) in PTEN-deficient breast cancers for personalized therapy. *Breast Cancer Research and Treatment*, **2018**, 169, 277-286	4.4	10
629	IL-6 and IL-10 are associated with good prognosis in early stage invasive breast cancer patients. *Cancer Immunology, Immunotherapy*, **2018**, 67, 537-549	7.4	40
628	High nuclear MSK1 is associated with longer survival in breast cancer patients. *Journal of Cancer Research and Clinical Oncology*, **2018**, 144, 509-517	4.9	9
627	Germline pathogenic variants in PALB2 and other cancer-predisposing genes in families with hereditary diffuse gastric cancer without CDH1 mutation: a whole-exome sequencing study. *The Lancet Gastroenterology and Hepatology*, **2018**, 3, 489-498	18.8	58
626	Diagnostic concordance of reporting lymphovascular invasion in breast cancer. *Journal of Clinical Pathology*, **2018**, 71, 802-805	3.9	8
625	Mediator complex (MED) 7: a biomarker associated with good prognosis in invasive breast cancer, especially ER+ luminal subtypes. *British Journal of Cancer*, **2018**, 118, 1142-1151	8.7	6
624	The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypes. *British Journal of Cancer*, **2018**, 118, 1115-1122	8.7	23
623	Prognostic significance of tumor-infiltrating lymphocytes in ductal carcinoma in situ of the breast. *Modern Pathology*, **2018**, 31, 1226-1236	9.8	40
622	Breast cancer histologic grading using digital microscopy: concordance and outcome association. *Journal of Clinical Pathology*, **2018**, 71, 680-686	3.9	20
621	Checkpoint Kinase 1 Expression Predicts Poor Prognosis in Nigerian Breast Cancer Patients. *Molecular Diagnosis and Therapy*, **2018**, 22, 79-90	4.5	8
620	Thioredoxin-interacting protein is an independent risk stratifier for breast ductal carcinoma in situ. *Modern Pathology*, **2018**, 31, 1807-1815	9.8	21

619	Saccharomyces cerevisiae-like 1 (SEC14L1) is a prognostic factor in breast cancer associated with lymphovascular invasion. *Modern Pathology*, **2018**, 31, 1675-1682	9.8	7
618	Intra-operative spectroscopic assessment of surgical margins during breast conserving surgery. *Breast Cancer Research*, **2018**, 20, 69	8.3	54
617	Clinicopathological and prognostic significance of Ras association and pleckstrin homology domains 1 (RAPH1) in breast cancer. *Breast Cancer Research and Treatment*, **2018**, 172, 61-68	4.4	4
616	Impact of breast cancer grade discordance on prediction of outcome. *Histopathology*, **2018**, 73, 904-915	7.3	15
615	Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas. *Nature Communications*, **2018**, 9, 1816	17.4	82
614	The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours. *Breast Cancer Research*, **2018**, 20, 21	8.3	58
613	Management and 5-year outcomes in 9938 women with screen-detected ductal carcinoma in situ: the UK Sloane Project. *European Journal of Cancer*, **2018**, 101, 210-219	7.5	34
612	MYC regulation of glutamine-proline regulatory axis is key in luminal B breast cancer. *British Journal of Cancer*, **2018**, 118, 258-265	8.7	47
611	Diagnostic challenges in papillary lesions of the breast. *Pathology*, **2018**, 50, 100-110	1.6	25
610	Invasion in breast lesions: the role of the epithelial-stroma barrier. *Histopathology*, **2018**, 72, 1075-1083	7.3	13
609	Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response-Targeted Therapies in Breast Cancer. *Molecular Cancer Therapeutics*, **2018**, 17, 306-315	6.1	37
608	HER2 challenge contest: a detailed assessment of automated HER2 scoring algorithms in whole slide images of breast cancer tissues. *Histopathology*, **2018**, 72, 227-238	7.3	51
607	Altered glutamine metabolism in breast cancer; subtype dependencies and alternative adaptations. *Histopathology*, **2018**, 72, 183-190	7.3	33
606	Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. *Journal of Clinical Oncology*, **2018**, 36, 2105-2122	2.2	646
605	Low expression of G protein-coupled oestrogen receptor 1 (GPER) is associated with adverse survival of breast cancer patients. *Oncotarget*, **2018**, 9, 25946-25956	3.3	25
604	Prolyl-4-hydroxylase βsubunit 2 (P4HA2) expression is a predictor of poor outcome in breast ductal carcinoma in situ (DCIS). *British Journal of Cancer*, **2018**, 119, 1518-1526	8.7	21
603	Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition. *Clinical Cancer Research*, **2018**, 24, 6594-6610	12.9	36
602	Loss-of-function mutations in ATP6AP1 and ATP6AP2 in granular cell tumors. *Nature Communications*, **2018**, 9, 3533	17.4	60

601	Treatment strategies and survival outcomes in older women with breast cancer: A comparative study between the FOCUS cohort and Nottingham cohort. *Journal of Geriatric Oncology*, **2018**, 9, 635-641	3.6	3
600	Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. *Archives of Pathology and Laboratory Medicine*, **2018**, 142, 1364-1382	5	295
599	Heterogeneity of tumour-infiltrating lymphocytes in breast cancer and its prognostic significance. *Histopathology*, **2018**, 73, 887-896	7.3	38
598	Clinicopathological and molecular characteristics of Ku 70/80 expression in Nigerian breast cancer and its potential therapeutic implications. *Pathology Research and Practice*, **2017**, 213, 27-33	3.4	3
597	Amplified centrosomes and mitotic index display poor concordance between patient tumors and cultured cancer cells. *Scientific Reports*, **2017**, 7, 43984	4.9	12
596	Prognostic stratification of oestrogen receptor-positive HER2-negative lymph node-negative class of breast cancer. *Histopathology*, **2017**, 70, 622-631	7.3	18
595	Clinical Impact of Tumor DNA Repair Expression and T-cell Infiltration in Breast Cancers. *Cancer Immunology Research*, **2017**, 5, 292-299	12.5	40
594	Review of the national external quality assessment (EQA) scheme for breast pathology in the UK. *Journal of Clinical Pathology*, **2017**, 70, 51-57	3.9	28
593	Solid Papillary Breast Carcinomas Resembling the Tall Cell Variant of Papillary Thyroid Neoplasms: A Unique Invasive Tumor With Indolent Behavior. *American Journal of Surgical Pathology*, **2017**, 41, 887-895	6.7	38
592	Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections. *Breast Cancer Research and Treatment*, **2017**, 164, 341-348	4.4	33
591	Phenotypic characterisation of breast cancer: the role of CDC42. *Breast Cancer Research and Treatment*, **2017**, 164, 317-325	4.4	18
590	Factors influencing local control in patients undergoing breast conservation surgery for ductal carcinoma in situ. *Breast*, **2017**, 31, 181-185	3.6	2
589	Chemokine (C-C motif) receptor 7 (CCR7) associates with the tumour immune microenvironment but not progression in invasive breast carcinoma. *Journal of Pathology: Clinical Research*, **2017**, 3, 105-114	5.3	5
588	Prognostic significance of tumour infiltrating B lymphocytes in breast ductal carcinoma in situ. *Histopathology*, **2017**, 71, 258-268	7.3	36
587	Characterisation of male breast cancer: a descriptive biomarker study from a large patient series. *Scientific Reports*, **2017**, 7, 45293	4.9	29
586	Immunoprofile of metaplastic carcinomas of the breast. *Histopathology*, **2017**, 70, 975-985	7.3	39
585	A Case-Matched Gender Comparison Transcriptomic Screen Identifies eIF4E and eIF5 as Potential Prognostic Markers in Male Breast Cancer. *Clinical Cancer Research*, **2017**, 23, 2575-2583	12.9	10
584	Reply to Rosen. *Modern Pathology*, **2017**, 30, 1505-1506	9.8	0

583	Rho-GTPase activating-protein 18: a biomarker associated with good prognosis in invasive breast cancer. *British Journal of Cancer*, **2017**, 117, 1176-1184	8.7	10
582	Novel immunohistochemistry-based signatures to predict metastatic site of triple-negative breast cancers. *British Journal of Cancer*, **2017**, 117, 826-834	8.7	7
581	The Spectrum of Triple-Negative Breast Disease: High- and Low-Grade Lesions. *American Journal of Pathology*, **2017**, 187, 2139-2151	5.8	78
580	Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. *Lancet, The*, **2017**, 390, 1048-1060	40	269
579	An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation. *Breast Cancer Research*, **2017**, 19, 58	8.3	100
578	Caspase-3 and caspase-8 expression in breast cancer: caspase-3 is associated with survival. *Apoptosis: an International Journal on Programmed Cell Death*, **2017**, 22, 357-368	5.4	85
577	Breast conservation in ductal carcinoma in situ (DCIS): what defines optimal margins?. *Histopathology*, **2017**, 70, 681-692	7.3	11
576	Clinicopathological and Functional Significance of RECQL1 Helicase in Sporadic Breast Cancers. *Molecular Cancer Therapeutics*, **2017**, 16, 239-250	6.1	12
575	Diagnostic concordance of breast pathologists: lessons from the National Health Service Breast Screening Programme Pathology External Quality Assurance Scheme. *Histopathology*, **2017**, 70, 632-642	7.3	14
574	Genetic analysis of microglandular adenosis and acinic cell carcinomas of the breast provides evidence for the existence of a low-grade triple-negative breast neoplasia family. *Modern Pathology*, **2017**, 30, 69-84	9.8	34
573	Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer. *Clinical Cancer Research*, **2017**, 23, 2991-3002	12.9	33
572	Further evidence to support bimodality of oestrogen receptor expression in breast cancer. *Histopathology*, **2017**, 70, 456-465	7.3	9
571	Oestrogen receptor negative early operable primary breast cancer in older women-Biological characteristics and long-term clinical outcome. *PLoS ONE*, **2017**, 12, e0188528	3.7	1
570	Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer. *Oncotarget*, **2017**, 8, 14897-14911	3.3	28
569	The localization of pre mRNA splicing factor PRPF38B is a novel prognostic biomarker that may predict survival benefit of trastuzumab in patients with breast cancer overexpressing HER2. *Oncotarget*, **2017**, 8, 112245-112257	3.3	1
568	Grading of Invasive Carcinoma **2017**, 87-95		1
567	Current trials to reduce surgical intervention in ductal carcinoma in situ of the breast: Critical review. *Breast*, **2017**, 35, 151-156	3.6	21
566	PKCÎAttenuates Jagged-1-Mediated Notch Signaling in ErbB-2-Positive Breast Cancer to Reverse Trastuzumab Resistance. *Clinical Cancer Research*, **2016**, 22, 175-86	12.9	17

565	SRC3 Phosphorylation at Serine 543 Is a Positive Independent Prognostic Factor in ER-Positive Breast Cancer. *Clinical Cancer Research*, **2016**, 22, 479-91	12.9	13
564	HAGE in Triple-Negative Breast Cancer Is a Novel Prognostic, Predictive, and Actionable Biomarker: A Transcriptomic and Protein Expression Analysis. *Clinical Cancer Research*, **2016**, 22, 905-14	12.9	13
563	Prognostic significance of androgen receptor expression in invasive breast cancer: transcriptomic and protein expression analysis. *Breast Cancer Research and Treatment*, **2016**, 159, 215-27	4.4	59
562	Clinicopathological and prognostic significance of mitogen-activated protein kinases (MAPK) in breast cancers. *Breast Cancer Research and Treatment*, **2016**, 159, 457-67	4.4	16
561	The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. *Nature Communications*, **2016**, 7, 11479	17.4	779
560	RECQL4 helicase has oncogenic potential in sporadic breast cancers. *Journal of Pathology*, **2016**, 238, 495-501	9.4	29
559	Construction of tissue microarrays from core needle biopsies - a systematic literature review. *Histopathology*, **2016**, 68, 323-32	7.3	12
558	Calpain-1 is associated with adverse relapse free survival in breast cancer: a confirmatory study. *Histopathology*, **2016**, 68, 1021-9	7.3	5
557	Expression of CDK7, Cyclin H, and MAT1 Is Elevated in Breast Cancer and Is Prognostic in Estrogen Receptor-Positive Breast Cancer. *Clinical Cancer Research*, **2016**, 22, 5929-5938	12.9	47
556	SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis. *Lancet Oncology, The*, **2016**, 17, 1004-1018	21.7	65
555	Bimodality of intratumor Ki67 expression is an independent prognostic factor of overall survival in patients with invasive breast carcinoma. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2016**, 468, 493-502	5.1	22
554	Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. *Lancet, The*, **2016**, 387, 866-73	40	114
553	Clinical utility of reverse phase protein array for molecular classification of breast cancer. *Breast Cancer Research and Treatment*, **2016**, 155, 25-35	4.4	13
552	Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio-resistance in breast cancer. *Molecular Oncology*, **2016**, 10, 213-23	7.9	26
551	Biological effects of fulvestrant on estrogen receptor positive human breast cancer: short, medium and long-term effects based on sequential biopsies. *International Journal of Cancer*, **2016**, 138, 146-59	7.5	20
550	The prognostic significance of STAT3 in invasive breast cancer: analysis of protein and mRNA expressions in large cohorts. *Breast Cancer Research and Treatment*, **2016**, 156, 9-20	4.4	22
549	MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours. *British Journal of Cancer*, **2016**, 114, 917-28	8.7	64
548	Clinicopathological and prognostic significance of RECQL5 helicase expression in breast cancers. *Carcinogenesis*, **2016**, 37, 63-71	4.6	25

547	Differing pattern of biological characteristics of early operable primary breast cancer according to age.. *Journal of Clinical Oncology*, **2016**, 34, e23272-e23272	2.2	0
546	Camptothecin targets WRN protein: mechanism and relevance in clinical breast cancer. *Oncotarget*, **2016**, 7, 13269-84	3.3	31
545	Potential of a novel technique for constructing tissue microarrays from core needle biopsy as seen in older women with primary breast cancer.. *Journal of Clinical Oncology*, **2016**, 34, e23283-e23283	2.2	
544	Multi-institutional study of triple negative breast cancer stratification by a metric that quantifies cell cycling kinetics.. *Journal of Clinical Oncology*, **2016**, 34, 1091-1091	2.2	
543	Identifying likely metastatic sites for triple negative breast cancers using immunohistochemical biomarkers.. *Journal of Clinical Oncology*, **2016**, 34, 1092-1092	2.2	
542	A combined HER3-EGFR score in triple-negative breast cancer: racial differences.. *Journal of Clinical Oncology*, **2016**, 34, e12560-e12560	2.2	
541	A retrospective study of SPAG5 expression and its clinical implications in >8,000 patients of ER positive (ER+) breast cancer (BC): Genomic, transcriptomic and protein analysis.. *Journal of Clinical Oncology*, **2016**, 34, 575-575	2.2	
540	A multi-institutional study of racial differences in androgen receptor status among triple-negative breast cancers.. *Journal of Clinical Oncology*, **2016**, 34, 1089-1089	2.2	0
539	Papillary carcinoma of the breast: diagnostic agreement and management implications. *Histopathology*, **2016**, 69, 862-870	7.3	16
538	Infiltrating epitheliosis of the breast: characterization of histological features, immunophenotype and genomic profile. *Histopathology*, **2016**, 68, 1030-9	7.3	21
537	Microglandular adenosis associated with triple-negative breast cancer is a neoplastic lesion of triple-negative phenotype harbouring TP53 somatic mutations. *Journal of Pathology*, **2016**, 238, 677-88	9.4	42
536	Impact of intratumoural heterogeneity on the assessment of Ki67 expression in breast cancer. *Breast Cancer Research and Treatment*, **2016**, 158, 287-95	4.4	10
535	Pleomorphic adenoma-like tumour of the breast. *Histopathology*, **2016**, 68, 405-10	7.3	11
534	Human epidermal growth factor receptor 2 testing in invasive breast cancer: should histological grade, type and oestrogen receptor status influence the decision to repeat testing?. *Histopathology* , **2016**, 69, 20-4	7.3	6
533	Impact of tissue sampling on accuracy of Ki67 immunohistochemistry evaluation in breast cancer. *Diagnostic Pathology*, **2016**, 11, 82	3	24
532	National survey of B1 and B2 reporting of breast needle core biopsies. *Journal of Clinical Pathology*, **2016**, 69, 271-4	3.9	1
531	Novel Immunohistochemical Based Biomarkers in Breast Cancer **2016**, 99-119		
530	Clinicopathologic Characteristics of Solid Papillary Carcinoma of the Breast. *American Journal of Surgical Pathology*, **2016**, 40, 1334-42	6.7	31

529	Nottingham prognostic index plus (NPI+) predicts risk of distant metastases in primary breast cancer. *Breast Cancer Research and Treatment*, **2016**, 157, 65-75	4.4	17
528	Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer. *Modern Pathology*, **2016**, 29, 1292-1305	9.8	52
527	Nottingham Prognostic Index Plus: Validation of a clinical decision making tool in breast cancer in an independent series. *Journal of Pathology: Clinical Research*, **2016**, 2, 32-40	5.3	24
526	An approach to the diagnosis of spindle cell lesions of the breast. *Histopathology*, **2016**, 68, 33-44	7.3	41
525	Clinical and biological significance of RAD51 expression in breast cancer: a key DNA damage response protein. *Breast Cancer Research and Treatment*, **2016**, 159, 41-53	4.4	28
524	Breast lesions of uncertain malignant nature and limited metastatic potential: proposals to improve their recognition and clinical management. *Histopathology*, **2016**, 68, 45-56	7.3	29
523	Phyllodes tumours of the breast: a consensus review. *Histopathology*, **2016**, 68, 5-21	7.3	220
522	A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancer. *Molecular Oncology*, **2015**, 9, 115-27	7.9	35
521	Nottingham Clinico-Pathological Response Index (NPRI) after neoadjuvant chemotherapy (Neo-ACT) accurately predicts clinical outcome in locally advanced breast cancer. *Clinical Cancer Research*, **2015**, 21, 1052-62	12.9	14
520	Transcriptomic and Protein Expression Analysis Reveals Clinicopathological Significance of Bloom Syndrome Helicase (BLM) in Breast Cancer. *Molecular Cancer Therapeutics*, **2015**, 14, 1057-65	6.1	32
519	Checkpoint kinase1 (CHK1) is an important biomarker in breast cancer having a role in chemotherapy response. *British Journal of Cancer*, **2015**, 112, 901-11	8.7	28
518	Updated UK Recommendations for HER2 assessment in breast cancer. *Journal of Clinical Pathology*, **2015**, 68, 93-9	3.9	155
517	KPNA2 is a nuclear export protein that contributes to aberrant localisation of key proteins and poor prognosis of breast cancer. *British Journal of Cancer*, **2015**, 112, 1929-37	8.7	43
516	Untangling the ATR-CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer. *Molecular Oncology*, **2015**, 9, 569-85	7.9	57
515	Prognostic and biological significance of peroxisome proliferator-activated receptor-gamma in luminal breast cancer. *Breast Cancer Research and Treatment*, **2015**, 150, 511-22	4.4	17
514	Biological and clinical significance of PARP1 protein expression in breast cancer. *Breast Cancer Research and Treatment*, **2015**, 149, 353-62	4.4	48
513	DNA damage response markers are differentially expressed in BRCA-mutated breast cancers. *Breast Cancer Research and Treatment*, **2015**, 150, 81-90	4.4	30
512	The mammalian target of rapamycin complex 1 (mTORC1) in breast cancer: the impact of oestrogen receptor and HER2 pathways. *Breast Cancer Research and Treatment*, **2015**, 150, 91-103	4.4	10

511	Markers of progression in early-stage invasive breast cancer: a predictive immunohistochemical panel algorithm for distant recurrence risk stratification. *Breast Cancer Research and Treatment*, **2015**, 151, 325-33	4.4	20
510	Brief fixation and hormone receptor expression in breast cancer. *American Journal of Surgical Pathology*, **2015**, 39, 425	6.7	
509	Clinical and biological significance of glucocorticoid receptor (GR) expression in breast cancer. *Breast Cancer Research and Treatment*, **2015**, 150, 335-46	4.4	59
508	Molecular Pathology of Precancerous Lesions of the Breast. *Molecular Pathology Library*, **2015**, 51-62		1
507	National guidelines and level of evidence: comments on some of the new recommendations in the American Society of Clinical Oncology and the College of American Pathologists human epidermal growth factor receptor 2 guidelines for breast cancer. *Journal of Clinical Oncology*, **2015**, 33, 1301-2	2.2	28
506	Molecular Classification of Breast Cancer. *Molecular Pathology Library*, **2015**, 137-155		
505	5-Carboxylcytosine levels are elevated in human breast cancers and gliomas. *Clinical Epigenetics*, **2015**, 7, 88	7.7	25
504	Prognostic factors in metaplastic carcinoma of the breast: a multi-institutional study. *British Journal of Cancer*, **2015**, 112, 283-9	8.7	67
503	KSR1 regulates BRCA1 degradation and inhibits breast cancer growth. *Oncogene*, **2015**, 34, 2103-14	9.2	11
502	The TRAIL system is over-expressed in breast cancer and FLIP a marker of good prognosis. *Journal of Cancer Research and Clinical Oncology*, **2015**, 141, 505-14	4.9	4
501	Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy. *Molecular Oncology*, **2015**, 9, 204-17	7.9	55
500	Papillary and neuroendocrine breast lesions: the WHO stance. *Histopathology*, **2015**, 66, 761-70	7.3	88
499	The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesis-generating study. *Journal of Pathology*, **2015**, 237, 166-78	9.4	42
498	Effective provision of a genetic screening program delivered to University students with limited resources. *American Journal of Medical Genetics, Part A*, **2015**, 167A, 922-4	2.5	1
497	Are acinic cell carcinomas of the breast and salivary glands distinct diseases?. *Histopathology*, **2015**, 67, 529-37	7.3	25
496	High-grade encapsulated papillary carcinoma of the breast: an under-recognized entity. *Histopathology*, **2015**, 66, 740-6	7.3	36
495	Ki67/SATB1 ratio is an independent prognostic factor of overall survival in patients with early hormone receptor-positive invasive ductal breast carcinoma. *Oncotarget*, **2015**, 6, 41134-45	3.3	13
494	Inflammatory breast cancer: time to standardise diagnosis assessment and management, and for the joining of forces to facilitate effective research. *British Journal of Cancer*, **2015**, 112, 1613-5	8.7	28

493	Molecular-Based Diagnostic, Prognostic and Predictive Tests in Breast Cancer. *Molecular Pathology Library*, **2015**, 177-195		1
492	Molecular Pathology of Breast Cancer Metastasis. *Molecular Pathology Library*, **2015**, 271-289		1
491	Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents. *Breast Cancer Research*, **2015**, 17, 59	8.3	42
490	Breast Neoplasms with Dermal Analogue Differentiation (Mammary Cylindroma): Report of 3 Cases and a Proposal for a New Terminology. *Pathobiology*, **2015**, 82, 172-8	3.6	2
489	ELF5 Drives Lung Metastasis in Luminal Breast Cancer through Recruitment of Gr1+ CD11b+ Myeloid-Derived Suppressor Cells. *PLoS Biology*, **2015**, 13, e1002330	9.7	44
488	FKBPL: a marker of good prognosis in breast cancer. *Oncotarget*, **2015**, 6, 12209-23	3.3	9
487	DNA repair prognostic index modelling reveals an essential role for base excision repair in influencing clinical outcomes in ER negative and triple negative breast cancers. *Oncotarget*, **2015**, 6, 21964-78	3.3	17
486	The pioneer factor PBX1 is a novel driver of metastatic progression in ER-positive breast cancer. *Oncotarget*, **2015**, 6, 21878-91	3.3	28
485	Transcriptomic and protein expression analysis of helicase antigen (HAGE) in triple negative breast cancer (TNBC) as a novel prognostic and predictive biomarker.. *Journal of Clinical Oncology*, **2015**, 33, 1093-1093	2.2	
484	Mechanistic and clinical analysis of Sperm associated antigen 5 (SPAG5) as a novel prognostic, predictive, actionable gene in Breast Cancer (BC).. *Journal of Clinical Oncology*, **2015**, 33, 1040-1040	2.2	
483	Characterisation of HER heterodimers in breast cancer using in situ proximity ligation assay. *Breast Cancer Research and Treatment*, **2014**, 144, 273-85	4.4	14
482	Assessment of microtubule-associated protein (MAP)-Tau expression as a predictive and prognostic marker in TACT; a trial assessing substitution of sequential docetaxel for FEC as adjuvant chemotherapy for early breast cancer. *Breast Cancer Research and Treatment*, **2014**, 144, 331-41	4.4	2
481	SUMOylation proteins in breast cancer. *Breast Cancer Research and Treatment*, **2014**, 144, 519-30	4.4	26
480	Clinicopathological significance of human apurinic/apyrimidinic endonuclease 1 (APE1) expression in oestrogen-receptor-positive breast cancer. *Breast Cancer Research and Treatment*, **2014**, 143, 411-21	4.4	21
479	The updated ASCO/CAP guideline recommendations for HER2 testing in the management of invasive breast cancer: a critical review of their implications for routine practice. *Histopathology*, **2014**, 64, 609-15	7.3	55
478	Human epidermal growth receptor-2 overexpressing early operable primary breast cancers in older (70 years) women: biology and clinical outcome in comparison with younger (. *Annals of Oncology*, **2014**, 25, 837-842	10.3	7
477	Epithelial mesenchymal transition in early invasive breast cancer: an immunohistochemical and reverse phase protein array study. *Breast Cancer Research and Treatment*, **2014**, 145, 339-48	4.4	44
476	C-Met in invasive breast cancer: is there a relationship with the basal-like subtype?. *Cancer*, **2014**, 120, 163-71	6.4	38

475	Prognostic significance of lymphatic invasion in lymph node-positive breast carcinoma: findings from a large case series with long-term follow-up using immunohistochemical endothelial marker. *Modern Pathology*, **2014**, 27, 1568-77	9.8	9
474	HAGE (DDX43) is a biomarker for poor prognosis and a predictor of chemotherapy response in breast cancer. *British Journal of Cancer*, **2014**, 110, 2450-61	8.7	20
473	Phosphorylation of activating transcription factor-2 (ATF-2) within the activation domain is a key determinant of sensitivity to tamoxifen in breast cancer. *Breast Cancer Research and Treatment*, **2014**, 147, 295-309	4.4	9
472	The effect of delay in fixation on HER2 expression in invasive carcinoma of the breast assessed with immunohistochemistry and in situ hybridisation. *Journal of Clinical Pathology*, **2014**, 67, 573-5	3.9	14
471	Adverse prognostic and predictive significance of low DNA-dependent protein kinase catalytic subunit (DNA-PKcs) expression in early-stage breast cancers. *Breast Cancer Research and Treatment*, **2014**, 146, 309-20	4.4	10
470	ERK1/2 is related to oestrogen receptor and predicts outcome in hormone-treated breast cancer. *Breast Cancer Research and Treatment*, **2014**, 147, 25-37	4.4	13
469	HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer. *Breast Cancer Research and Treatment*, **2014**, 145, 33-44	4.4	26
468	Prognostic and biological significance of proliferation and HER2 expression in the luminal class of breast cancer. *Breast Cancer Research and Treatment*, **2014**, 145, 317-30	4.4	10
467	A methodology to ensure and improve accuracy of Ki67 labelling index estimation by automated digital image analysis in breast cancer tissue. *Breast Cancer Research*, **2014**, 16, R35	8.3	72
466	DNA polymerase θ deficiency is linked to aggressive breast cancer: a comprehensive analysis of gene copy number, mRNA and protein expression in multiple cohorts. *Molecular Oncology*, **2014**, 8, 520-32	7.9	27
465	Genomic and protein expression analysis reveals flap endonuclease 1 (FEN1) as a key biomarker in breast and ovarian cancer. *Molecular Oncology*, **2014**, 8, 1326-38	7.9	77
464	DACH1: its role as a classifier of long term good prognosis in luminal breast cancer. *PLoS ONE*, **2014**, 9, e84428	3.7	19
463	Biological characteristics and clinical outcome of triple negative primary breast cancer in older women - comparison with their younger counterparts. *PLoS ONE*, **2014**, 9, e100573	3.7	20
462	Towards intra-operative diagnosis of tumours during breast conserving surgery by selective-sampling Raman micro-spectroscopy. *Physics in Medicine and Biology*, **2014**, 59, 6141-52	3.8	67
461	PIASγ expression in relation to clinicopathological, tumour factors and survival in indigenous black breast cancer women. *Journal of Clinical Pathology*, **2014**, 67, 301-6	3.9	9
460	A study of ductal versus non-ductal invasive breast carcinomas in older women: long-term clinical outcome and comparison with their younger counterparts. *Breast Cancer Research and Treatment*, **2014**, 147, 671-4	4.4	4
459	Nottingham Prognostic Index Plus (NPI+): a modern clinical decision making tool in breast cancer. *British Journal of Cancer*, **2014**, 110, 1688-97	8.7	68
458	Clinicopathological significance of ATM-Chk2 expression in sporadic breast cancers: a comprehensive analysis in large cohorts. *Neoplasia*, **2014**, 16, 982-91	6.4	30

457	The kinase LMTK3 promotes invasion in breast cancer through GRB2-mediated induction of integrin 🞐 *Science Signaling*, **2014**, 7, ra58	8.8	26
456	Therapeutic targeting of integrin 🞐🞐 in breast cancer. *Journal of the National Cancer Institute*, **2014**, 106,	9.7	89
455	Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. *Annals of Oncology*, **2014**, 25, 1536-43	10.3	433
454	Is there a role for base excision repair in estrogen/estrogen receptor-driven breast cancers?. *Antioxidants and Redox Signaling*, **2014**, 21, 2262-8	8.4	19
453	Anti-nicastrin monoclonal antibodies elicit pleiotropic anti-tumour pharmacological effects in invasive breast cancer cells. *Breast Cancer Research and Treatment*, **2014**, 148, 455-62	4.4	18
452	Inclusion of KI67 significantly improves performance of the PREDICT prognostication and prediction model for early breast cancer. *BMC Cancer*, **2014**, 14, 908	4.8	33
451	Low calpain-9 is associated with adverse disease-specific survival following endocrine therapy in breast cancer. *BMC Cancer*, **2014**, 14, 995	4.8	14
450	Immunoglobulin free light chains are biomarkers of poor prognosis in basal-like breast cancer and are potential targets in tumor-associated inflammation. *Oncotarget*, **2014**, 5, 3159-67	3.3	27
449	Involvement of metformin and AMPK in the radioresponse and prognosis of luminal versus basal-like breast cancer treated with radiotherapy. *Oncotarget*, **2014**, 5, 12936-49	3.3	39
448	Developing and evaluation of a new clinicopathologic response index after neoadjuvant chemotherapy as a predictor of clinical outcomes in locally advanced breast cancers.. *Journal of Clinical Oncology*, **2014**, 32, 1083-1083	2.2	
447	Tamoxifen versus anastrozole as primary endocrine therapy in older women with early operable primary breast cancer.. *Journal of Clinical Oncology*, **2014**, 32, e11533-e11533	2.2	2
446	Predicting chemotherapy response in invasive breast cancer.. *Journal of Clinical Oncology*, **2014**, 32, 1084-1084	2.2	
445	Intracellular intermolecular relationships of LKB1 in breast cancer.. *Journal of Clinical Oncology*, **2014**, 32, 554-554	2.2	
444	Pathology and biology of breast cancer **2014**, 20-43		
443	Molecular profiling of breast cancer in Nigerian women identifies an altered p53 pathway as a major mechanism underlying its poor prognosis compared with British counterpart. *Malaysian Journal of Pathology*, **2014**, 36, 3-17	1.7	5
442	A randomized trial to assess the biological activity of short-term (pre-surgical) fulvestrant 500 mg plus anastrozole versus fulvestrant 500 mg alone or anastrozole alone on primary breast cancer. *Breast Cancer Research*, **2013**, 15, R18	8.3	22
441	A quantifier-based fuzzy classification system for breast cancer patients. *Artificial Intelligence in Medicine*, **2013**, 58, 175-84	7.4	18
440	Identification of key clinical phenotypes of breast cancer using a reduced panel of protein biomarkers. *British Journal of Cancer*, **2013**, 109, 1886-94	8.7	34

439   Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings. *Annals of Oncology*, **2013**, 24, 2801-7   10.3   57

438   Single-strand selective monofunctional uracil-DNA glycosylase (SMUG1) deficiency is linked to aggressive breast cancer and predicts response to adjuvant therapy. *Breast Cancer Research and Treatment*, **2013**, 142, 515-27   4.4   22

437   Benign hidradenoma masquerading as ductal breast cancer-a rare case of false-positive recurrence in cancer follow-up. *Breast Journal*, **2013**, 19, 670-1   1.2   1

436   The oestrogen receptor coactivator CARM1 has an oncogenic effect and is associated with poor prognosis in breast cancer. *Breast Cancer Research and Treatment*, **2013**, 140, 307-16   4.4   34

435   Clinicopathological significance of KU70/KU80, a key DNA damage repair protein in breast cancer. *Breast Cancer Research and Treatment*, **2013**, 139, 301-10   4.4   46

434   Authors' reply: Combining two antibodies to define E-cadherin loss of expression in non-lobular breast carcinomas: when less is more. *Histopathology*, **2013**, 63, 440-3   7.3

433   Outcome of pure mucocele-like lesions diagnosed on breast core biopsy. *Histopathology*, **2013**, 62, 894-8   7.3   37

432   Targeting XRCC1 deficiency in breast cancer for personalized therapy. *Cancer Research*, **2013**, 73, 1621-34   10.1   71

431   Lack of expression of the proteins GMPR2 and PPARα are associated with the basal phenotype and patient outcome in breast cancer. *Breast Cancer Research and Treatment*, **2013**, 137, 127-37   4.4   15

430   The microRNA maturation regulator Drosha is an independent predictor of outcome in breast cancer patients. *Breast Cancer Research and Treatment*, **2013**, 137, 139-53   4.4   17

429   Cytoplasmic localization of alteration/deficiency in activation 3 (ADA3) predicts poor clinical outcome in breast cancer patients. *Breast Cancer Research and Treatment*, **2013**, 137, 721-31   4.4   13

428   Identification of novel breast cancer-associated transcripts by UniGene database mining and gene expression analysis in normal and malignant cells. *Genes Chromosomes and Cancer*, **2013**, 52, 316-29   5

427   Biology of primary breast cancer in older women treated by surgery: with correlation with long-term clinical outcome and comparison with their younger counterparts. *British Journal of Cancer*, **2013**, 108, 1042-51   8.7   49

426   Guidelines and considerations for conducting experiments using tissue microarrays. *Histopathology*, **2013**, 62, 827-39   7.3   50

425   Characteristics of basal cytokeratin expression in breast cancer. *Breast Cancer Research and Treatment*, **2013**, 139, 23-37   4.4   28

424   Phosphorylation of AKT pathway proteins is not predictive of benefit of taxane therapy in early breast cancer. *Breast Cancer Research and Treatment*, **2013**, 138, 773-81   4.4   9

423   The shaping and functional consequences of the microRNA landscape in breast cancer. *Nature*, **2013**, 497, 378-82   50.4   321

422   Further evidence that E-cadherin is not a tumour suppressor gene in invasive ductal carcinoma of the breast: an immunohistochemical study. *Histopathology*, **2013**, 62, 695-701   7.3   23

421	Do primary mammary osteosarcoma and chondrosarcoma exist? A review of a large multi-institutional series of malignant matrix-producing breast tumours. *Breast*, **2013**, 22, 13-8	3.6	34
420	SHON is a novel estrogen-regulated oncogene in mammary carcinoma that predicts patient response to endocrine therapy. *Cancer Research*, **2013**, 73, 6951-62	10.1	5
419	Pleomorphic lobular carcinoma of the breast: is it a prognostically significant pathological subtype independent of histological grade?. *Modern Pathology*, **2013**, 26, 496-501	9.8	33
418	Comparison of the PharmDx immunohistochemical system with standard methods for assessing estrogen and progesterone receptors in invasive carcinoma of the breast. *Applied Immunohistochemistry and Molecular Morphology*, **2013**, 21, 90-3	1.9	2
417	Cell Proliferation (KI-67) Expression Is Associated with Poorer Prognosis in Nigerian Compared to British Breast Cancer Women. *ISRN Oncology*, **2013**, 2013, 675051		11
416	Myoepithelial and epithelial-myoepithelial, mesenchymal and fibroepithelial breast lesions: updates from the WHO Classification of Tumours of the Breast 2012. *Journal of Clinical Pathology*, **2013**, 66, 465-70	3.9	82
415	Lobular neoplasia of the breast revisited with emphasis on the role of E-cadherin immunohistochemistry. *American Journal of Surgical Pathology*, **2013**, 37, e1-11	6.7	109
414	Abstract B046: Therapeutic targeting of integrin ⬛⬛ in high-risk breast cancer **2013**,		3
413	Histological risk factors, prognostic indicators and staging **2013**, 236-249		
412	Evaluation of flap endonuclease-1 (FEN1) as a prognostic, predictive, and therapeutic target in breast (BC) and ovarian cancer (OVC).. *Journal of Clinical Oncology*, **2013**, 31, 1016-1016	2.2	
411	Human epidermal growth receptor-2 overexpressing early operable primary breast cancers in older (⬛0 years) women: Biology and clinical outcome in comparison with younger (. *Journal of Clinical Oncology*, **2013**, 31, e11608-e11608	2.2	
410	Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer. *Breast Cancer Research*, **2012**, 14, R3	8.3	94
409	Current issues in diagnostic breast pathology. *Journal of Clinical Pathology*, **2012**, 65, 771-85	3.9	24
408	Loss of Dicer expression is associated with breast cancer progression and recurrence. *Breast Cancer Research and Treatment*, **2012**, 135, 403-13	4.4	69
407	Molecular characteristics and prognostic features of breast cancer in Nigerian compared with UK women. *Breast Cancer Research and Treatment*, **2012**, 135, 555-69	4.4	38
406	TOMM34 expression in early invasive breast cancer: a biomarker associated with poor outcome. *Breast Cancer Research and Treatment*, **2012**, 136, 419-27	4.4	20
405	Incorporation of expert variability into breast cancer treatment recommendation in designing clinical protocol guided fuzzy rule system models. *Journal of Biomedical Informatics*, **2012**, 45, 447-59	10.2	24
404	The prognostic and predictive power of redox protein expression for anthracycline-based chemotherapy response in locally advanced breast cancer. *Modern Pathology*, **2012**, 25, 1106-16	9.8	18

403	Phyllodes Tumor of the Breast **2012**, 243-256		2
402	Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. *Nature*, **2012**, 481, 389-93	50.4	1011
401	A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -positive breast cancers. *Journal of Pathology*, **2012**, 227, 29-41	9.4	44
400	The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. *Nature*, **2012**, 486, 346-52	50.4	3479
399	The prognostic significance of lymphovascular invasion in invasive breast carcinoma. *Cancer*, **2012**, 118, 3670-80	6.4	145
398	Fatty acid binding protein 7 expression and its sub-cellular localization in breast cancer. *Breast Cancer Research and Treatment*, **2012**, 134, 519-29	4.4	20
397	The prognostic significance of B lymphocytes in invasive carcinoma of the breast. *Breast Cancer Research and Treatment*, **2012**, 132, 545-53	4.4	181
396	LMTK3 expression in breast cancer: association with tumor phenotype and clinical outcome. *Breast Cancer Research and Treatment*, **2012**, 132, 537-44	4.4	29
395	EpCAM expression is an indicator of recurrence in basal-like breast cancer. *Breast Cancer Research and Treatment*, **2012**, 133, 575-82	4.4	20
394	A CD44?/CD24+ phenotype is a poor prognostic marker in early invasive breast cancer. *Breast Cancer Research and Treatment*, **2012**, 133, 979-95	4.4	79
393	Overexpression of a novel cell cycle regulator ecdysoneless in breast cancer: a marker of poor prognosis in HER2/neu-overexpressing breast cancer patients. *Breast Cancer Research and Treatment*, **2012**, 134, 171-80	4.4	16
392	A review of the biological and clinical characteristics of luminal-like oestrogen receptor-positive breast cancer. *Histopathology*, **2012**, 60, 854-63	7.3	18
391	Concordance of HER2 status assessed on needle core biopsy and surgical specimens of invasive carcinoma of the breast. *Histopathology*, **2012**, 60, 880-4	7.3	34
390	Re-audit of revised method for assessing the mitotic component of histological grade in needle core biopsies of invasive carcinoma of the breast. *Histopathology*, **2012**, 60, 1166-7	7.3	3
389	Encapsulated papillary carcinoma of the breast: a study of invasion associated markers. *Journal of Clinical Pathology*, **2012**, 65, 710-4	3.9	33
388	Calpain system protein expression in basal-like and triple-negative invasive breast cancer. *Annals of Oncology*, **2012**, 23, 2289-2296	10.3	49
387	Observer agreement comparing the use of virtual slides with glass slides in the pathology review component of the POSH breast cancer cohort study. *Journal of Clinical Pathology*, **2012**, 65, 403-8	3.9	24
386	Infiltrative epitheliosis of the breast. *Journal of Clinical Pathology*, **2012**, 65, 766-8	3.9	8

#	Reference	IF	Cites
385	CD8(+) T lymphocytes infiltrating breast cancer: A promising new prognostic marker?. *OncoImmunology*, **2012**, 1, 364-365	7.2	33
384	Objective assessment of blood and lymphatic vessel invasion and association with macrophage infiltration in cutaneous melanoma. *Modern Pathology*, **2012**, 25, 493-504	9.8	91
383	PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2. *British Journal of Cancer*, **2012**, 107, 800-7	8.7	130
382	The value of examination of multiple levels of mammary needle core biopsy specimens taken for investigation of lesions other than calcification. *Journal of Clinical Pathology*, **2012**, 65, 1097-9	3.9	8
381	Long-term (37 years) clinical outcome of older women with early operable primary breast cancer managed in a dedicated clinic. *Annals of Oncology*, **2012**, 23, 1465-71	10.3	20
380	A randomised trial of primary tamoxifen versus mastectomy plus adjuvant tamoxifen in fit elderly women with invasive breast carcinoma of high oestrogen receptor content: long-term results at 20 years of follow-up. *Annals of Oncology*, **2012**, 23, 2296-2300	10.3	39
379	Low-estrogen receptor-positive breast cancer: the impact of tissue sampling, choice of antibody, and molecular subtyping. *Journal of Clinical Oncology*, **2012**, 30, 2929-30; author reply 2931	2.2	13
378	Discovering Hidden Pathways in Bioinformatics. *Lecture Notes in Computer Science*, **2012**, 49-60	0.9	
377	A study of sperm-associated antigen 5 (SPAG5) in predicting response to anthracycline (ATC)/platinum chemotherapies (CT) in breast (BC) and ovarian cancers (OVC).. *Journal of Clinical Oncology*, **2012**, 30, 1098-1098	2.2	
376	HAGE (DDX43) protein expression as an independent biomarker of poor clinical outcome of breast cancer (BC) and potential as a therapeutic target for ER-negative BC.. *Journal of Clinical Oncology*, **2012**, 30, 1013-1013	2.2	1
375	Targeting XRCC1 (X-ray repair cross-complementing gene 1) deficiency in tumors for personalized cancer therapy.. *Journal of Clinical Oncology*, **2012**, 30, 1014-1014	2.2	
374	Detection and quantification of microRNAs in laser-microdissected formalin-fixed paraffin-embedded breast cancer tissues. *Methods in Molecular Biology*, **2011**, 755, 119-42	1.4	3
373	Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. *Lancet Oncology, The*, **2011**, 12, 21-9	21.7	371
372	Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. *Journal of Clinical Oncology*, **2011**, 29, 1949-55	2.2	961
371	erbB3 recruitment of insulin receptor substrate 1 modulates insulin-like growth factor receptor signalling in oestrogen receptor-positive breast cancer cell lines. *Breast Cancer Research*, **2011**, 13, R93	8.3	17
370	Expression of thioredoxin system and related peroxiredoxin proteins is associated with clinical outcome in radiotherapy treated early stage breast cancer. *Radiotherapy and Oncology*, **2011**, 100, 308-13	5.3	39
369	Lymphatic Expression of CLEVER-1 in Breast Cancer and Its Relationship with Lymph Node Metastasis. *Analytical Cellular Pathology*, **2011**, 34, 67-78	3.4	5
368	Modern classification of breast cancer: should we stick with morphology or convert to molecular profile characteristics. *Advances in Anatomic Pathology*, **2011**, 18, 255-67	5.1	53

367	Encapsulated papillary carcinoma of the breast: an invasive tumor with excellent prognosis. *American Journal of Surgical Pathology*, **2011**, 35, 1093-103	6.7	95
366	Outcome of breast lesions diagnosed as lesion of uncertain malignant potential (B3) or suspicious of malignancy (B4) on needle core biopsy, including detailed review of epithelial atypia. *Histopathology*, **2011**, 58, 626-32	7.3	49
365	Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer. *Nature Medicine*, **2011**, 17, 715-9	50.5	101
364	Comparison of methods for handling missing data on immunohistochemical markers in survival analysis of breast cancer. *British Journal of Cancer*, **2011**, 104, 693-9	8.7	40
363	Long-term clinical outcome of oestrogen receptor-positive operable primary breast cancer in older women: a large series from a single centre. *British Journal of Cancer*, **2011**, 104, 1393-400	8.7	35
362	Histological grade of invasive carcinoma of the breast assessed on needle core biopsy - modifications to mitotic count assessment to improve agreement with surgical specimens. *Histopathology*, **2011**, 59, 543-8	7.3	21
361	Early primary breast cancer in the elderly - pattern of presentation and treatment. *Surgical Oncology*, **2011**, 20, 7-12	2.5	18
360	Calpastatin is associated with lymphovascular invasion in breast cancer. *Breast*, **2011**, 20, 413-8	3.6	24
359	The prognostic significance of computerised tomography findings in women with liver metastases from breast cancer. *Breast*, **2011**, 20, 455-9	3.6	2
358	Pathological and mammographic prognostic factors for screen detected cancers in a multi-centre randomised, controlled trial of mammographic screening in women from age 40 to 48 years. *Breast*, **2011**, 20, 525-8	3.6	13
357	Optimising the management of primary breast cancer in older women - a report of a multi-disciplinary study day. *Breast*, **2011**, 20, 581-4	3.6	2
356	Biological and clinical implications of nicastrin expression in invasive breast cancer. *Breast Cancer Research and Treatment*, **2011**, 125, 43-53	4.4	23
355	CTEN (C-terminal tensin-like), a novel oncogene overexpressed in invasive breast carcinoma of poor prognosis. *Breast Cancer Research and Treatment*, **2011**, 126, 47-54	4.4	37
354	An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer. *Breast Cancer Research and Treatment*, **2011**, 127, 99-108	4.4	129
353	Clinicopathologic and molecular significance of phospho-Akt expression in early invasive breast cancer. *Breast Cancer Research and Treatment*, **2011**, 127, 407-16	4.4	45
352	Microcephalin is a new novel prognostic indicator in breast cancer associated with BRCA1 inactivation. *Breast Cancer Research and Treatment*, **2011**, 127, 639-48	4.4	27
351	MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups. *Breast Cancer Research and Treatment*, **2011**, 127, 591-9	4.4	82
350	RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype. *Breast Cancer Research and Treatment*, **2011**, 128, 315-26	4.4	33

349	FOXO3a nuclear localisation is associated with good prognosis in luminal-like breast cancer. *Breast Cancer Research and Treatment*, **2011**, 129, 11-21	4.4	59
348	Alpha- and beta-adrenergic receptor (AR) protein expression is associated with poor clinical outcome in breast cancer: an immunohistochemical study. *Breast Cancer Research and Treatment*, **2011**, 130, 457-63	4.4	70
347	Clustering of protein expression data: a benchmark of statistical and neural approaches. *Soft Computing*, **2011**, 15, 1459-1469	3.5	4
346	A non-parametric version of the naive Bayes classifier. *Knowledge-Based Systems*, **2011**, 24, 775-784	7.3	71
345	Objective assessment of lymphatic and blood vascular invasion in lymph node-negative breast carcinoma: findings from a large case series with long-term follow-up. *Journal of Pathology*, **2011**, 223, 358-65	9.4	63
344	Metaplastic breast carcinoma: tumour histogenesis or dedifferentiation?. *Journal of Pathology*, **2011**, 224, 434-7	9.4	35
343	ZNF703 is a common Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epithelium. *EMBO Molecular Medicine*, **2011**, 3, 167-80	12	97
342	Characterization and outcome of breast needle core biopsy diagnoses of lesions of uncertain malignant potential (B3) in abnormalities detected by mammographic screening. *International Journal of Cancer*, **2011**, 129, 1417-24	7.5	70
341	Calpain-1 expression is associated with relapse-free survival in breast cancer patients treated with trastuzumab following adjuvant chemotherapy. *International Journal of Cancer*, **2011**, 129, 1773-80	7.5	29
340	Redox protein expression predicts radiotherapeutic response in early-stage invasive breast cancer patients. *International Journal of Radiation Oncology Biology Physics*, **2011**, 79, 1532-40	4	22
339	Breast carcinomas with borderline (2+) HER2 immunohistochemistry: percentage of cells with complete membrane staining for HER2 and the frequency of HER2 amplification. *Journal of Clinical Pathology*, **2011**, 64, 490-2	3.9	24
338	Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer. *Journal of Clinical Oncology*, **2011**, 29, 4273-8	2.2	549
337	p53 status identifies two subgroups of triple-negative breast cancers with distinct biological features. *Japanese Journal of Clinical Oncology*, **2011**, 41, 172-9	2.8	49
336	Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. *Modern Pathology*, **2011**, 24, 157-67	9.8	447
335	Lymphatic and blood vessels in basal and triple-negative breast cancers: characteristics and prognostic significance. *Modern Pathology*, **2011**, 24, 774-85	9.8	84
334	Lymph-node metastases in invasive lobular carcinoma are different from those in ductal carcinoma of the breast. *Journal of Clinical Pathology*, **2011**, 64, 995-1000	3.9	34
333	The number of women who would need to be screened regularly by mammography to prevent one death from breast cancer. *Journal of Medical Screening*, **2011**, 18, 210-2	1.4	22
332	Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers. *Human Molecular Genetics*, **2011**, 20, 4732-47	5.6	21

331	Lymphatic expression of CLEVER-1 in breast cancer and its relationship with lymph node metastasis. *Analytical Cellular Pathology*, **2011**, 34, 67-78	3.4	4
330	Understanding the HER family in breast cancer: interaction with ligands, dimerization and treatments. *Histopathology*, **2010**, 56, 560-72	7.3	52
329	Comparison of margin assessment by radial and shave sections in wide local excision specimens for invasive carcinoma of the breast. *Histopathology*, **2010**, 56, 573-80	7.3	10
328	Reproducibility in the diagnosis of needle core biopsies of non-palpable breast lesions: an international study using virtual slides published on the world-wide web. *Histopathology*, **2010**, 56, 720-6	7.3	7
327	Histological grading of breast cancer on needle core biopsy: the role of immunohistochemical assessment of proliferation. *Histopathology*, **2010**, 57, 212-9	7.3	32
326	Radiological and pathological size estimations of pure ductal carcinoma in situ of the breast, specimen handling and the influence on the success of breast conservation surgery: a review of 2564 cases from the Sloane Project. *British Journal of Cancer*, **2010**, 102, 285-93	8.7	43
325	A new pathological system for grading DCIS with improved prediction of local recurrence: results from the UKCCCR/ANZ DCIS trial. *British Journal of Cancer*, **2010**, 103, 94-100	8.7	95
324	BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. *British Journal of Cancer*, **2010**, 103, 668-75	8.7	218
323	Topo2 protein expression predicts response to anthracycline combination neo-adjuvant chemotherapy in locally advanced primary breast cancer. *British Journal of Cancer*, **2010**, 103, 1794-800	8.7	21
322	Determination of HER2 amplification in primary breast cancer using dual-colour chromogenic in situ hybridization is comparable to fluorescence in situ hybridization: a European multicentre study involving 168 specimens. *Histopathology*, **2010**, 56, 472-80	7.3	67
321	Tubular carcinoma of the breast: further evidence to support its excellent prognosis. *Journal of Clinical Oncology*, **2010**, 28, 99-104	2.2	129
320	Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. *PLoS Medicine*, **2010**, 7, e1000279	11.6	616
319	Erdheim-chester disease presenting as bilateral clinically malignant breast masses. *American Journal of Surgical Pathology*, **2010**, 34, 584-8	6.7	28
318	Intraductal proliferative lesions of the breast: morphology, associated risk and molecular biology. *Modern Pathology*, **2010**, 23 Suppl 2, S1-7	9.8	70
317	Histological features of medullary carcinoma and prognosis in triple-negative basal-like carcinomas of the breast. *Modern Pathology*, **2010**, 23, 1357-63	9.8	43
316	Ecatenin/Wnt signalling pathway in fibromatosis, metaplastic carcinomas and phyllodes tumours of the breast. *Modern Pathology*, **2010**, 23, 1438-48	9.8	100
315	Genomic gain of 5p15 leads to over-expression of Misu (NSUN2) in breast cancer. *Cancer Letters*, **2010**, 289, 71-80	9.9	59
314	Screen-detected malignant breast lesions diagnosed following benign (B2) or normal (B1) needle core biopsy diagnoses. *European Journal of Cancer*, **2010**, 46, 1835-40	7.5	6

313	A UK NEQAS ICC and ISH multicentre study using the Kreatech Poseidon HER2 FISH probe: intersite variation can be rigorously controlled using FISH. *Histopathology*, **2010**, 56, 297-304	7.3	8
312	Lobular breast carcinoma and its variants. *Seminars in Diagnostic Pathology*, **2010**, 27, 49-61	4.3	95
311	Breast cancer prognostic classification in the molecular era: the role of histological grade. *Breast Cancer Research*, **2010**, 12, 207	8.3	459
310	Clinical and biological significance of E-cadherin protein expression in invasive lobular carcinoma of the breast. *American Journal of Surgical Pathology*, **2010**, 34, 1472-9	6.7	110
309	Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen. *Breast Cancer Research and Treatment*, **2010**, 119, 283-93	4.4	155
308	A validated gene expression profile for detecting clinical outcome in breast cancer using artificial neural networks. *Breast Cancer Research and Treatment*, **2010**, 120, 83-93	4.4	47
307	The prognostic significance of PELP1 expression in invasive breast cancer with emphasis on the ER-positive luminal-like subtype. *Breast Cancer Research and Treatment*, **2010**, 120, 603-12	4.4	66
306	The proteins FABP7 and OATP2 are associated with the basal phenotype and patient outcome in human breast cancer. *Breast Cancer Research and Treatment*, **2010**, 121, 41-51	4.4	43
305	PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis. *Breast Cancer Research and Treatment*, **2010**, 122, 45-53	4.4	63
304	Combinatorial biomarker expression in breast cancer. *Breast Cancer Research and Treatment*, **2010**, 120, 293-308	4.4	150
303	Adenosquamous carcinoma of breast in a 19 years old woman: a case report. *World Journal of Surgical Oncology*, **2010**, 8, 44	3.4	18
302	A vision to optimise the management of primary breast cancer in older women. *Breast*, **2010**, 19, 153-5	3.6	4
301	Growth fraction as a predictor of response to chemotherapy in node-negative breast cancer. *International Journal of Cancer*, **2010**, 126, 1761-9	7.5	29
300	A methodology to identify consensus classes from clustering algorithms applied to immunohistochemical data from breast cancer patients. *Computers in Biology and Medicine*, **2010**, 40, 318-30	7	42
299	The biological, clinical and prognostic implications of p53 transcriptional pathways in breast cancers. *Journal of Pathology*, **2010**, 220, 419-34	9.4	49
298	Proposal for a modified grading system based on mitotic index and Bcl2 provides objective determination of clinical outcome for patients with breast cancer. *Journal of Pathology*, **2010**, 222, 388-99	9.4	34
297	Beta-Blocker Drug Therapy Reduces Secondary Cancer Formation in Breast Cancer and Improves Cancer Specific Survival. *Oncotarget*, **2010**, 1, 628-638	3.3	332
296	Chromogenic in situ hybridization: a multicenter study comparing silver in situ hybridization with FISH. *American Journal of Clinical Pathology*, **2009**, 132, 514-20	1.9	33

295	Elevated Src kinase activity attenuates Tamoxifen response in vitro and is associated with poor prognosis clinically. *Cancer Biology and Therapy*, **2009**, 8, 1550-8	4.6	56
294	Influence of E-cadherin expression on the mammographic appearance of invasive nonlobular breast carcinoma detected at screening. *Radiology*, **2009**, 253, 51-5	20.5	11
293	External quality assurance of HER2 FISH and ISH testing: three years of the UK national external quality assurance scheme. *American Journal of Clinical Pathology*, **2009**, 131, 106-11	1.9	31
292	Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. *Cancer Research*, **2009**, 69, 3802-9	10.1	340
291	Biological profile of oestrogen receptor positive primary breast cancers in the elderly and response to primary endocrine therapy. *Critical Reviews in Oncology/Hematology*, **2009**, 72, 76-82	7	9
290	The biological and clinical characteristics of breast carcinoma with mixed ductal and lobular morphology. *Breast Cancer Research and Treatment*, **2009**, 114, 243-50	4.4	38
289	No association of TGFB1 L10P genotypes and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a multi-center cohort study. *Breast Cancer Research and Treatment*, **2009**, 115, 185-92	4.4	11
288	Tumor size is an unreliable predictor of prognosis in basal-like breast cancers and does not correlate closely with lymph node status. *Breast Cancer Research and Treatment*, **2009**, 117, 199-204	4.4	69
287	Loss of expression of chromosome 16q genes DPEP1 and CTCF in lobular carcinoma in situ of the breast. *Breast Cancer Research and Treatment*, **2009**, 113, 59-66	4.4	42
286	Lymphatic and angiogenic characteristics in breast cancer: morphometric analysis and prognostic implications. *Breast Cancer Research and Treatment*, **2009**, 113, 261-73	4.4	48
285	Patho-biological aspects of basal-like breast cancer. *Breast Cancer Research and Treatment*, **2009**, 113, 411-22	4.4	61
284	Mixed micropapillary-ductal carcinomas of the breast: a genomic and immunohistochemical analysis of morphologically distinct components. *Journal of Pathology*, **2009**, 218, 301-15	9.4	65
283	Vascular invasion in breast cancer; an overview of recent prognostic developments and molecular pathophysiological mechanisms. *Histopathology*, **2009**, 55, 1-9	7.3	26
282	The expression of ERalpha, ERbeta and PR in lobular carcinoma in situ of the breast determined using laser microdissection and real-time PCR. *Histopathology*, **2009**, 54, 419-27	7.3	9
281	Pigmented mammary Paget's disease: not a melanoma. *Histopathology*, **2009**, 54, 614-7	7.3	7
280	The NRG1 gene is frequently silenced by methylation in breast cancers and is a strong candidate for the 8p tumour suppressor gene. *Oncogene*, **2009**, 28, 4041-52	9.2	58
279	Sonographic correlations with the new molecular classification of invasive breast cancer. *European Radiology*, **2009**, 19, 2342-8	8	48
278	CT staging of loco-regional breast cancer recurrence. A worthwhile practice?. *Clinical Radiology*, **2009**, 64, 885-90	2.9	13

277	Screen-detected breast lesions with malignant needle core biopsy diagnoses and no malignancy identified in subsequent surgical excision specimens (potential false-positive diagnosis). *European Journal of Cancer*, **2009**, 45, 1162-1167	7.5	17
276	Triple-negative/basal-like breast cancer: review. *Pathology*, **2009**, 41, 40-7	1.6	204
275	Investigating AP-2 and YY1 protein expression as a cause of high HER2 gene transcription in breast cancers with discordant HER2 gene amplification. *Breast Cancer Research*, **2009**, 11, R90	8.3	37
274	Dysregulated expression of Fau and MELK is associated with poor prognosis in breast cancer. *Breast Cancer Research*, **2009**, 11, R60	8.3	109
273	Linguistic rulesets extracted from a quantifier-based fuzzy classification system **2009**,		5
272	Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. *Lancet, The*, **2009**, 373, 1681-92	40	144
271	Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. *Clinical Cancer Research*, **2009**, 15, 2302-10	12.9	371
270	Special theme issue: breast pathology. *Pathology*, **2009**, 41, 1-2	1.6	
269	Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas). *Modern Pathology*, **2008**, 21, 1060-1; author reply 1061-2	9.8	10
268	Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype. *British Journal of Cancer*, **2008**, 99, 327-34	8.7	122
267	Implications of inconsistent measurement of ER status in non-invasive breast cancer: a study of 1,684 cases from the Sloane Project. *Breast Journal*, **2008**, 14, 33-8	1.2	17
266	Is acinic cell carcinoma a variant of secretory carcinoma? A FISH study using ETV6'split apart' probes. *Histopathology*, **2008**, 52, 840-6	7.3	69
265	Predictive value of needle core biopsy diagnoses of lesions of uncertain malignant potential (B3) in abnormalities detected by mammographic screening. *Histopathology*, **2008**, 53, 650-7	7.3	113
264	High-resolution array CGH clarifies events occurring on 8p in carcinogenesis. *BMC Cancer*, **2008**, 8, 288	4.8	36
263	Incidence of intramammary nodes in completion mastectomy specimens after axillary node sampling: implications for breast conserving surgery. *Breast*, **2008**, 17, 195-8	3.6	15
262	Vacuum-assisted excision of breast lesions of uncertain malignant potential (B3) - an alternative to surgery in selected cases. *Breast*, **2008**, 17, 546-9	3.6	35
261	IL-17 expression by breast-cancer-associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines. *Breast Cancer Research*, **2008**, 10, R95	8.3	166
260	A Comparison of Three Different Methods for Classification of Breast Cancer Data **2008**,		10

259	Expression of BRCA1 protein in breast cancer and its prognostic significance. *Human Pathology*, **2008**, 39, 857-65	3.7	115
258	Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes. *European Journal of Cancer*, **2008**, 44, 73-83	7.5	164
257	Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance. *European Journal of Cancer*, **2008**, 44, 1541-51	7.5	74
256	Audit of performance of needle core biopsy diagnoses of screen detected breast lesions. *European Journal of Cancer*, **2008**, 44, 2580-6	7.5	28
255	The mammographic correlations of a new immunohistochemical classification of invasive breast cancer. *Clinical Radiology*, **2008**, 63, 1228-35	2.9	22
254	Basal-like breast cancer: a critical review. *Journal of Clinical Oncology*, **2008**, 26, 2568-81	2.2	657
253	Breast carcinoma with basal phenotype: mammographic findings. *American Journal of Roentgenology*, **2008**, 191, 346-51	5.4	36
252	Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. *Journal of Clinical Oncology*, **2008**, 26, 3153-8	2.2	336
251	Poor-prognosis estrogen receptor-positive breast cancer identified by histopathologic subclassification. *Clinical Cancer Research*, **2008**, 14, 6625-33	12.9	12
250	Morphologic and molecular evolutionary pathways of low nuclear grade invasive breast cancers and their putative precursor lesions: further evidence to support the concept of low nuclear grade breast neoplasia family. *American Journal of Surgical Pathology*, **2008**, 32, 513-23	6.7	189
249	Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. *Journal of Clinical Oncology*, **2008**, 26, 1059-65	2.2	360
248	HER2 testing in the UK: further update to recommendations. *Journal of Clinical Pathology*, **2008**, 61, 818-24	3.4	107
247	Clinical importance of estrogen receptor beta isoforms in breast cancer. *Journal of Clinical Oncology*, **2008**, 26, 5825; author reply 5825-6	2.2	7
246	Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients. *Clinical Cancer Research*, **2008**, 14, 5228-35	12.9	187
245	Are triple-negative and basal-like breast cancer synonymous?. *Clinical Cancer Research*, **2008**, 14, 618; author reply 618-9	12.9	42
244	Impact of basal-like breast carcinoma determination for a more specific therapy. *Pathobiology*, **2008**, 75, 95-103	3.6	25
243	Assessing agreement between multiple raters with missing rating information, applied to breast cancer tumour grading. *PLoS ONE*, **2008**, 3, e2925	3.7	14
242	Expression profiling technology: its contribution to our understanding of breast cancer. *Histopathology*, **2008**, 52, 67-81	7.3	34

241	Pathological features of primary breast cancer in the elderly based on needle core biopsies--a large series from a single centre. *Critical Reviews in Oncology/Hematology*, **2008**, 67, 263-7	7	41
240	CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome. *Breast Cancer Research and Treatment*, **2008**, 109, 325-35	4.4	110
239	The prognostic significance of steroid receptor co-regulators in breast cancer: co-repressor NCOR2/SMRT is an independent indicator of poor outcome. *Breast Cancer Research and Treatment*, **2008**, 110, 427-37	4.4	49
238	Histologic grading is an independent prognostic factor in invasive lobular carcinoma of the breast. *Breast Cancer Research and Treatment*, **2008**, 111, 121-7	4.4	96
237	The Nottingham prognostic index for invasive carcinoma of the breast. *Pathology and Oncology Research*, **2008**, 14, 113-5	2.6	45
236	The significance of lobular neoplasia on needle core biopsy of the breast. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2008**, 452, 473-9	5.1	61
235	Differential subcellular localisation of the tumour suppressor protein LIMD1 in breast cancer correlates with patient survival. *International Journal of Cancer*, **2008**, 123, 2247-53	7.5	16
234	Cluster-based visualisation with scatter matrices. *Pattern Recognition Letters*, **2008**, 29, 1814-1823	4.7	22
233	The emerging role of the LIV-1 subfamily of zinc transporters in breast cancer. *Molecular Medicine*, **2007**, 13, 396-406	6.2	176
232	The p53 positive Bcl-2 negative phenotype is an independent marker of prognosis in breast cancer. *International Journal of Cancer*, **2007**, 120, 1311-7	7.5	34
231	Prognostic markers in triple-negative breast cancer. *Cancer*, **2007**, 109, 25-32	6.4	963
230	Underestimation of malignancy of breast core-needle biopsy: concepts and precise overall and category-specific estimates. *Cancer*, **2007**, 109, 487-95	6.4	150
229	A gene-expression signature to predict survival in breast cancer across independent data sets. *Oncogene*, **2007**, 26, 1507-16	9.2	191
228	Using array-comparative genomic hybridization to define molecular portraits of primary breast cancers. *Oncogene*, **2007**, 26, 1959-70	9.2	88
227	The expression of Wilms' tumour-1 and Ca125 in invasive micropapillary carcinoma of the breast. *Histopathology*, **2007**, 51, 824-8	7.3	30
226	Prognostic significance of vascular endothelial cell growth factors -A, -C and -D in breast cancer and their relationship with angio- and lymphangiogenesis. *British Journal of Cancer*, **2007**, 96, 1092-100	8.7	153
225	Laboratory handling and histology reporting of breast specimens from patients who have received neoadjuvant chemotherapy. *Histopathology*, **2007**, 50, 409-17	7.3	98
224	Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression. *Histopathology*, **2007**, 50, 434-8	7.3	132

223	Histological features useful in the distinction of phyllodes tumour and fibroadenoma on needle core biopsy of the breast. *Histopathology*, **2007**, 51, 336-44	7.3	100
222	Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2007**, 451, 19-25	5.1	123
221	External quality assurance of HER2 fluorescence in situ hybridisation testing: results of a UK NEQAS pilot scheme. *Journal of Clinical Pathology*, **2007**, 60, 816-9	3.9	27
220	The reliability of assessment of oestrogen receptor expression on needle core biopsy specimens of invasive carcinomas of the breast. *Journal of Clinical Pathology*, **2007**, 60, 299-302	3.9	53
219	The collagen receptor Endo180 (CD280) Is expressed on basal-like breast tumor cells and promotes tumor growth in vivo. *Cancer Research*, **2007**, 67, 10230-40	10.1	68
218	BEX2 is overexpressed in a subset of primary breast cancers and mediates nerve growth factor/nuclear factor-kappaB inhibition of apoptosis in breast cancer cell lines. *Cancer Research*, **2007**, 67, 6725-36	10.1	72
217	Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy. *Journal of Clinical Oncology*, **2007**, 25, 4423-30	2.2	59
216	The ubiquitin-binding protein p62 is expressed in breast cancers showing features of aggressive disease. *Endocrine-Related Cancer*, **2007**, 14, 73-80	5.7	83
215	Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. *Journal of Clinical Oncology*, **2007**, 25, 4772-8	2.2	213
214	Regulation of p53 tetramerization and nuclear export by ARC. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 20826-31	11.5	89
213	Basal phenotype: a powerful prognostic factor in small screen-detected invasive breast cancer with long-term follow-up. *Journal of Medical Screening*, **2007**, 14, 210-4	1.4	21
212	High frequency of coexistence of columnar cell lesions, lobular neoplasia, and low grade ductal carcinoma in situ with invasive tubular carcinoma and invasive lobular carcinoma. *American Journal of Surgical Pathology*, **2007**, 31, 417-26	6.7	227
211	Improved methods of detection of lymphovascular invasion demonstrate that it is the predominant method of vascular invasion in breast cancer and has important clinical consequences. *American Journal of Surgical Pathology*, **2007**, 31, 1825-33	6.7	142
210	Are triple-negative tumours and basal-like breast cancer synonymous?. *Breast Cancer Research*, **2007**, 9, 404; author reply 405	8.3	83
209	Serum epidermal growth factor receptor and HER2 expression in primary and metastatic breast cancer patients. *Breast Cancer Research*, **2007**, 9, R75	8.3	59
208	Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells. *Breast Cancer Research*, **2007**, 9, R50	8.3	40
207	FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis. *Breast Cancer Research*, **2007**, 9, R23	8.3	211
206	High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. *Genome Biology*, **2007**, 8, R215	18.3	230

205	MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. *Genome Biology*, **2007**, 8, R214	18.3	742
204	An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. *Genome Biology*, **2007**, 8, R157	18.3	383
203	Are triple negative tumours and basal-like breast cancer synonymous?. *Breast Cancer Research*, **2007**, 9, R80	8.3	6
202	Upregulation of MICA on high-grade invasive operable breast carcinoma. *Cancer Immunity*, **2007**, 7, 17		38
201	Expression of the membrane complement regulatory protein CD59 (protectin) is associated with reduced survival in colorectal cancer patients. *Cancer Immunology, Immunotherapy*, **2006**, 55, 973-80	7.4	51
200	Chromosome 16 tumor-suppressor genes in breast cancer. *Genes Chromosomes and Cancer*, **2006**, 45, 527-35	5	69
199	Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis. *International Journal of Cancer*, **2006**, 118, 6-10	7.5	174
198	Expression of the stress-related MHC class I chain-related protein MICA is an indicator of good prognosis in colorectal cancer patients. *International Journal of Cancer*, **2006**, 118, 1445-52	7.5	112
197	Is mammographic spiculation an independent, good prognostic factor in screening-detected invasive breast cancer?. *American Journal of Roentgenology*, **2006**, 187, 1377-80	5.4	57
196	Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. *Clinical Cancer Research*, **2006**, 12, 2468-75	12.9	163
195	Adult leydig cell tumors of the testis caused by germline fumarate hydratase mutations. *Journal of Clinical Endocrinology and Metabolism*, **2006**, 91, 3071-5	5.6	90
194	Interval breast cancers: prognostic features and survival by subtype and time since screening. *Journal of Medical Screening*, **2006**, 13, 115-22	1.4	24
193	EMAP-II-dependent lymphocyte killing is associated with hypoxia in colorectal cancer. *British Journal of Cancer*, **2006**, 95, 735-43	8.7	10
192	A consensus prognostic gene expression classifier for ER positive breast cancer. *Genome Biology*, **2006**, 7, R101	18.3	75
191	The management of lobular carcinoma in situ (LCIS). Is LCIS the same as ductal carcinoma in situ (DCIS)?. *European Journal of Cancer*, **2006**, 42, 2205-11	7.5	75
190	Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. *European Journal of Cancer*, **2006**, 42, 3149-56	7.5	164
189	Phyllodes Tumor of the Breast **2006**, 209-217		3
188	Polymorphous adenocarcinoma of the breast. Report of three cases. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2006**, 448, 29-34	5.1	20

187	Cytoplasmic expression of p27(kip1) is associated with a favourable prognosis in colorectal cancer patients. *World Journal of Gastroenterology*, **2006**, 12, 6299-304	5.6	8
186	Histologic Grade **2006**, 225-233		18
185	Evidence that the p53 negative / Bcl-2 positive phenotype is an independent indicator of good prognosis in colorectal cancer: a tissue microarray study of 460 patients. *World Journal of Surgical Oncology*, **2005**, 3, 47	3.4	34
184	High expression of Lewis y/b antigens is associated with decreased survival in lymph node negative breast carcinomas. *Breast Cancer Research*, **2005**, 7, R780-7	8.3	67
183	Columnar cell lesions of the breast: the missing link in breast cancer progression? A morphological and molecular analysis. *American Journal of Surgical Pathology*, **2005**, 29, 734-46	6.7	219
182	Clinical value of epidermal growth factor receptor expression in primary breast cancer. *Advances in Anatomic Pathology*, **2005**, 12, 271-3	5.1	33
181	E-cadherin expression in invasive non-lobular carcinoma of the breast and its prognostic significance. *Histopathology*, **2005**, 46, 685-93	7.3	132
180	Breast pathology practice: most common problems in a consultation service. *Histopathology*, **2005**, 47, 445-57	7.3	37
179	A 1 Mb minimal amplicon at 8p11-12 in breast cancer identifies new candidate oncogenes. *Oncogene*, **2005**, 24, 5235-45	9.2	130
178	Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. *Modern Pathology*, **2005**, 18, 26-35	9.8	196
177	Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. *Modern Pathology*, **2005**, 18, 1295-304	9.8	257
176	High-resolution analysis of 16q22.1 in breast carcinoma using DNA amplifiable probes (multiplex amplifiable probe hybridization technique) and immunohistochemistry. *International Journal of Cancer*, **2005**, 114, 720-9	7.5	18
175	High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. *International Journal of Cancer*, **2005**, 116, 340-50	7.5	443
174	Total loss of MHC class I is an independent indicator of good prognosis in breast cancer. *International Journal of Cancer*, **2005**, 117, 248-55	7.5	115
173	Do poor-prognosis breast tumours express membrane cofactor proteins (CD46)?. *Cancer Immunology, Immunotherapy*, **2005**, 54, 149-56	7.4	28
172	Current Developments in the Analysis of Proteomic Data: Artificial Neural Network Data Mining Techniques for the Identification of Proteomic Biomarkers Related to Breast Cancer. *Current Proteomics*, **2005**, 2, 15-29	0.7	19
171	Histological risk factors, prognostic indicators **2005**, 254-265		
170	Loss of CD55 is associated with aggressive breast tumors. *Clinical Cancer Research*, **2004**, 10, 2797-803	12.9	39

169	Discrepancies in current practice of pathological evaluation of sentinel lymph nodes in breast cancer. Results of a questionnaire based survey by the European Working Group for Breast Screening Pathology. *Journal of Clinical Pathology*, **2004**, 57, 695-701	3.9	129
168	Expression of the transcription factor CTCF in invasive breast cancer: a candidate gene located at 16q22.1. *British Journal of Cancer*, **2004**, 91, 1591-6	8.7	28
167	Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. *British Journal of Cancer*, **2004**, 91, 1532-42	8.7	195
166	Identification of carcinoma cells in peripheral blood samples of patients with advanced breast carcinoma using RT-PCR amplification of CK7 and MUC1. *Breast*, **2004**, 13, 35-41	3.6	20
165	Are medullary breast cancers an indication for BRCA1 mutation screening? A mutation analysis of 42 cases of medullary breast cancer. *Breast Cancer Research and Treatment*, **2004**, 85, 81-8	4.4	15
164	Phenotypic similarities in bilateral breast cancer. *Breast Cancer Research and Treatment*, **2004**, 85, 255-61	4.4	21
163	Mucoepidermoid carcinoma of the breast. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2004**, 444, 13-9	5.1	45
162	Consistency of staining and reporting of oestrogen receptor immunocytochemistry within the European Union--an inter-laboratory study. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2004**, 445, 119-28	5.1	36
161	Expression of luminal and basal cytokeratins in human breast carcinoma. *Journal of Pathology*, **2004**, 203, 661-71	9.4	442
160	Expression of E2F-4 in invasive breast carcinomas is associated with poor prognosis. *Journal of Pathology*, **2004**, 203, 754-61	9.4	33
159	Genetic counseling for hereditary pancreatitis--the role of molecular genetics testing for the cationic trypsinogen gene, cystic fibrosis and serine protease inhibitor Kazal type 1. *Gastroenterology Clinics of North America*, **2004**, 33, 839-54	4.4	20
158	Ductal carcinoma in situ: diagnosis and classification. *Current Diagnostic Pathology*, **2004**, 10, 204-210		3
157	Influence of annual mammography from age 40 on breast cancer pathology. *Human Pathology*, **2004**, 35, 1252-9	3.7	17
156	Beyond organ retention: the new human tissue bill. *Lancet, The*, **2004**, 364 Suppl 1, s42-3	40	3
155	Diagnosis of axillary nodal metastases by ultrasound-guided core biopsy in primary operable breast cancer. *British Journal of Cancer*, **2003**, 89, 1310-3	8.7	199
154	Correlation of histologic prognostic factors in core biopsies and therapeutic excisions of invasive breast carcinoma. *American Journal of Surgical Pathology*, **2003**, 27, 11-5	6.7	103
153	Breast tumor resembling the tall cell variant of papillary thyroid carcinoma: report of 5 cases. *American Journal of Surgical Pathology*, **2003**, 27, 1114-8	6.7	76
152	Excision biopsy findings of patients with breast needle core biopsies reported as suspicious of malignancy (B4) or lesion of uncertain malignant potential (B3). *Histopathology*, **2003**, 42, 331-6	7.3	87

151	A prototype methodology combining surface-enhanced laser desorption/ionization protein chip technology and artificial neural network algorithms to predict the chemoresponsiveness of breast cancer cell lines exposed to Paclitaxel and Doxorubicin under in vitro conditions. *Proteomics*, **2003**, 3, 1725-37	4.8	47
150	Malignant phyllodes tumours show stromal overexpression of c-myc and c-kit. *Journal of Pathology*, **2003**, 200, 59-64	9.4	77
149	Beta-catenin abnormalities and associated insulin-like growth factor overexpression are important in phyllodes tumours and fibroadenomas of the breast. *Journal of Pathology*, **2003**, 200, 627-32	9.4	45
148	Is the presence of mammographic comedo calcification really a prognostic factor for small screen-detected invasive breast cancers?. *Clinical Radiology*, **2003**, 58, 54-62	2.9	37
147	An immunohistochemical study of metaplastic spindle cell carcinoma, phyllodes tumor and fibromatosis of the breast. *Human Pathology*, **2003**, 34, 1009-15	3.7	129
146	The diagnosis and management of pre-invasive breast disease: ductal carcinoma in situ (DCIS) and atypical ductal hyperplasia (ADH)--current definitions and classification. *Breast Cancer Research*, **2003**, 5, 254-7	8.3	88
145	A randomised multicentre trial of modified CHOP versus MCOP in patients aged 65 years and over with aggressive non-Hodgkin's lymphoma. *Annals of Oncology*, **2003**, 14, 258-67	10.3	14
144	Retained human tissues: a molecular genetics goldmine or modern grave robbing? A legal approach to obtaining and using stored human samples. *Medicine and Law*, **2003**, 22, 357-72		4
143	HER-2 in breast cancer--methods of detection, clinical significance and future prospects for treatment. *Critical Reviews in Oncology/Hematology*, **2002**, 43, 231-44	7	26
142	Neuroendocrine differentiation and prognosis in breast adenocarcinoma. *Histopathology*, **2002**, 40, 215-22	7.3	107
141	The Wnt pathway, epithelial-stromal interactions, and malignant progression in phyllodes tumours. *Journal of Pathology*, **2002**, 196, 437-44	9.4	95
140	Diffraction-enhanced imaging: improved contrast and lower dose x-ray imaging **2002**,		11
139	Implications of pathologist concordance for breast cancer assessments in mammography screening from age 40 years. *Human Pathology*, **2002**, 33, 365-71	3.7	22
138	Extent of ductal carcinoma in situ within and surrounding invasive primary breast carcinoma. *British Journal of Surgery*, **2001**, 88, 1324-9	5.3	8
137	Breast cancer diagnosis using scattered x rays? **2001**, 4320, 547		4
136	Prognostic significance of synchronous and metachronous bilateral breast cancer. *World Journal of Surgery*, **2001**, 25, 1117-24	3.3	61
135	Analysis of short stature homeobox-containing gene (SHOX) and auxological phenotype in dyschondrosteosis and isolated Madelung deformity. *Human Genetics*, **2001**, 109, 551-8	6.3	51
134	An audit of "equivocal" (C3) and "suspicious" (C4) categories in fine needle aspiration cytology of the breast. *Cytopathology*, **2001**, 12, 219-26	1.3	32

133	Mitotic counting in surgical pathology: sampling bias, heterogeneity and statistical uncertainty. *Histopathology*, **2001**, 39, 1-8	7.3	30
132	Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. *International Journal of Cancer*, **2001**, 95, 247-54	7.5	196
131	Effect of dietary GLA+/-tamoxifen on the growth, ER expression and fatty acid profile of ER positive human breast cancer xenografts. *International Journal of Cancer*, **2001**, 92, 342-7	7.5	21
130	Change in expression of ER, bcl-2 and MIB1 on primary tamoxifen and relation to response in ER positive breast cancer. *Breast Cancer Research and Treatment*, **2001**, 65, 135-44	4.4	31
129	Growth pattern of ductal carcinoma in situ (DCIS): a retrospective analysis based on mammographic findings. *British Journal of Cancer*, **2001**, 85, 225-7	8.7	32
128	Detecting which invasive cancers at mammographic screening saves lives?. *Journal of Medical Screening*, **2001**, 8, 86-90	1.4	12
127	Screen detected ductal carcinoma in situ (DCIS): overdiagnosis or an obligate precursor of invasive disease?. *Journal of Medical Screening*, **2001**, 8, 149-51	1.4	55
126	Pathological validation and significance of micrometastasis in sentinel nodes in primary breast cancer. *Breast Cancer Research*, **2001**, 3, 113-6	8.3	32
125	Predicting invasion in mammographically detected microcalcification. *Clinical Radiology*, **2001**, 56, 828-32	2.9	62
124	Gamma linolenic acid with tamoxifen as primary therapy in breast cancer. *International Journal of Cancer*, **2000**, 85, 643-8	7.5	69
123	Biological and clinical associations of c-jun activation in human breast cancer. *International Journal of Cancer*, **2000**, 89, 177-86	7.5	66
122	A possible divergent role for the oestrogen receptor alpha and beta subtypes in clinical breast cancer. *International Journal of Cancer*, **2000**, 89, 209-12	7.5	36
121	Breast cancer diagnosis using scattered X-rays. *Journal of Synchrotron Radiation*, **2000**, 7, 348-52	2.4	71
120	Metaplastic carcinoma of the breast arising within complex sclerosing lesion: a report of five cases. *Histopathology*, **2000**, 36, 203-9	7.3	73
119	Microinvasive lobular carcinoma of the breast. *Histopathology*, **2000**, 37, 477-8	7.3	2
118	Elastin: mutational spectrum in supravalvular aortic stenosis. *European Journal of Human Genetics*, **2000**, 8, 955-63	5.3	125
117	c-erbB-4 protein expression in human breast cancer. *British Journal of Cancer*, **2000**, 82, 1163-70	8.7	82
116	Loss of heterozygosity in bilateral breast cancer. *Breast Cancer Research and Treatment*, **2000**, 64, 241-51	4.4	32

115	Pathological assessment of sentinel lymph-node biopsies in patients with breast cancer. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2000**, 436, 97-101	5.1	8
114	Histologic grading of breast cancer: linkage of patient outcome with level of pathologist agreement. *Modern Pathology*, **2000**, 13, 730-5	9.8	102
113	Molecular analysis of phyllodes tumors reveals distinct changes in the epithelial and stromal components. *American Journal of Pathology*, **2000**, 156, 1093-8	5.8	72
112	When have mammographic calcifications been adequately sampled at needle core biopsy?. *Clinical Radiology*, **2000**, 55, 548-53	2.9	41
111	Ultrasound guided core biopsy of suspicious mammographic calcifications using high frequency and power Doppler ultrasound. *Clinical Radiology*, **2000**, 55, 390-4	2.9	33
110	Digital imaging improves upright stereotactic core biopsy of mammographic microcalcifications. *Clinical Radiology*, **2000**, 55, 374-7	2.9	19
109	Needle core biopsy of the breast. *Current Diagnostic Pathology*, **2000**, 6, 200-205		6
108	Value of contralateral surveillance mammography for primary breast cancer follow-up. *World Journal of Surgery*, **2000**, 24, 983-7; discussion 988-9	3.3	19
107	Pathological prognostic factors in breast cancer. *Critical Reviews in Oncology/Hematology*, **1999**, 31, 209-23	7.7	119
106	Microinvasive carcinoma of the breast: diagnostic criteria and clinical relevance. *Histopathology*, **1999**, 35, 470-2	7.3	7
105	Anti-gonadotrophin releasing hormone antibodies inhibit the growth of MCF7 human breast cancer xenografts. *British Journal of Cancer*, **1999**, 80, 352-9	8.7	18
104	Endocrine response and resistance in breast cancer: a role for the transcription factor Fos. *International Journal of Cancer*, **1999**, 84, 54-61	7.5	17
103	BRCA1 expression levels predict distant metastasis of sporadic breast cancers. *International Journal of Cancer*, **1999**, 84, 258-62	7.5	51
102	Allelic imbalance at the LKB1 (STK11) locus in tumours from patients with Peutz-Jeghers' syndrome provides evidence for a hamartoma-(adenoma)-carcinoma sequence. *Journal of Pathology*, **1999**, 188, 9-13	9.4	71
101	Immunohistochemical analysis reveals a tumour suppressor-like role for the transcription factor AP-2 in invasive breast cancer. *Journal of Pathology*, **1999**, 189, 514-20	9.4	87
100	Clinical and histological predictors of contralateral breast cancer. *European Journal of Surgical Oncology*, **1999**, 25, 584-9	3.6	91
99	Bilateral breast carcinomas: do they have similar mammographic features?. *Clinical Radiology*, **1999**, 54, 434-7	2.9	4
98	Mammographic features of ductal carcinoma in situ (DCIS) present on previous mammography. *Clinical Radiology*, **1999**, 54, 644-6	2.9	48

97	BRCA1 expression levels predict distant metastasis of sporadic breast cancers **1999**, 84, 258		2
96	c-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer. *Oncogene*, **1998**, 17, 1949-57	9.2	106
95	Long-term follow-up of elderly patients randomized to primary tamoxifen or wedge mastectomy as initial therapy for operable breast cancer. *Breast*, **1998**, 7, 335-339	3.6	61
94	Prediction of local recurrence of ductal carcinoma in situ of the breast using five histological classifications: a comparative study with long follow-up. *Human Pathology*, **1998**, 29, 915-23	3.7	69
93	The accuracy of breast ultrasound in the evaluation of clinically benign discrete, symptomatic breast lumps. *Clinical Radiology*, **1998**, 53, 490-2	2.9	45
92	Prognostic factors affecting disease-free survival in patients with Hodgkin's disease stages IA and IIA treated initially with radiotherapy alone in a single centre during 1973 to 1992. *Radiotherapy and Oncology*, **1998**, 49, 15-9	5.3	2
91	Oestrogen-regulated genes in breast cancer: association of pLIV1 with response to endocrine therapy. *British Journal of Cancer*, **1998**, 77, 1653-6	8.7	12
90	erbB signalling in clinical breast cancer: relationship to endocrine sensitivity. *Endocrine-Related Cancer*, **1997**, 4, 297-305	5.7	3
89	Laminin and collagen IV subunit distribution in normal and neoplastic tissues of colorectum and breast. *British Journal of Cancer*, **1997**, 75, 221-9	8.7	51
88	The detection of ductal carcinoma in situ at mammographic screening enables the diagnosis of small, grade 3 invasive tumours. *British Journal of Cancer*, **1997**, 75, 542-4	8.7	34
87	A comparison outcome of male breast cancer with female breast cancer. *American Journal of Surgery*, **1997**, 173, 185-8	2.7	88
86	Early-onset breast cancer--histopathological and prognostic considerations. *British Journal of Cancer*, **1997**, 75, 1318-23	8.7	152
85	Mammographic and pathological features of breast cancer detected at first incident round screening. *Breast*, **1997**, 6, 259-265	3.6	6
84	Wire localization biopsies of non-palpable breast lesions: the use of the Nottingham localization device. *Breast*, **1997**, 6, 79-83	3.6	
83	Correlations between the mammographic features of screen detected invasive breast cancer and pathological prognostic factors. *Breast*, **1997**, 6, 146-149	3.6	24
82	Intratumoural heterogeneity of proliferation in invasive breast carcinoma evaluated with MIBI antibody. *Breast*, **1997**, 6, 171-176	3.6	27
81	Predictors of response to second-line endocrine therapy for breast cancer. *Breast Cancer Research and Treatment*, **1997**, 45, 219-24	4.4	30
80	Routine audit of breast fine needle aspiration (FNA) cytology specimens and aspirator inadequate rates. *Cytopathology*, **1997**, 8, 236-47	1.3	28

No.	Reference	IF	Cites
79	Screening interval breast cancers: mammographic features and prognosis factors. *Radiology*, **1996**, 199, 811-7	20.5	151
78	Is ipsilateral mammography worthwhile in Paget's disease of the breast?. *Clinical Radiology*, **1996**, 51, 35-8	2.9	46
77	DNA fingerprinting of benign and malignant breast lesions. *European Journal of Surgical Oncology*, **1996**, 22, 574-7	3.6	1
76	Use of immunocytochemistry in the diagnosis of metastatic carcinoma. *Annals of Medicine*, **1996**, 28, 297-300	1.5	9
75	Prognostic significance of serum c-erbB-2 protein in breast cancer patients. *Breast Cancer Research and Treatment*, **1996**, 40, 251-5	4.4	63
74	The role of pre-operative diagnosis in breast cancer. *Histopathology*, **1996**, 28, 563-6	7.3	32
73	United Kingdom national audit of breast fine needle aspiration cytology in 1990-91--organization and level of activity. *Cytopathology*, **1996**, 7, 316-25	1.3	3
72	UK national audit of breast fine needle aspiration cytology in 1990-91: diagnostic criteria. *Cytopathology*, **1996**, 7, 326-32	1.3	1
71	C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators. *British Journal of Cancer*, **1996**, 74, 229-33	8.7	103
70	Cathepsin D in primary breast carcinoma: adverse prognosis is associated with expression of cathepsin D in stromal cells. *Breast Cancer Research and Treatment*, **1995**, 33, 137-45	4.4	31
69	A cautionary note regarding the application of Ki-67 antibodies to paraffin-embedded breast cancers. *Journal of Pathology*, **1995**, 177, 285-93	9.4	18
68	Phyllodes tumours of the breast: a clinicopathological review of thirty-two cases. *Histopathology*, **1995**, 27, 205-18	7.3	193
67	Pathological prognostic factors in breast cancer. IV: Should you be a typer or a grader? A comparative study of two histological prognostic features in operable breast carcinoma. *Histopathology*, **1995**, 27, 219-26	7.3	146
66	The assessment of multiple variables on breast carcinoma fine needle aspiration (FNA) cytology specimens: method, preliminary results and prognostic associations. *Cytopathology*, **1995**, 6, 316-24	1.3	18
65	Metallothionein expression in human breast cancer. *British Journal of Cancer*, **1995**, 72, 968-72	8.7	72
64	Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. *British Journal of Cancer*, **1995**, 72, 1259-66	8.7	115
63	Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival. *British Journal of Cancer*, **1995**, 71, 146-9	8.7	145
62	Mammographic features of invasive lobular and invasive ductal carcinoma of the breast: a comparative analysis. *British Journal of Radiology*, **1995**, 68, 450-3	3.4	55

61	Prognostic value of immunocytochemistry of the primary tumour in patients with metastatic breast cancer. *Breast*, **1995**, 4, 277-281	3.6	
60	Immunocytochemical localization of Fos protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. *International Journal of Cancer*, **1995**, 64, 269-73	7.5	20
59	Local recurrence after simple mastectomy. *British Journal of Surgery*, **1994**, 81, 386-9	5.3	55
58	Ductal carcinoma in situ of the breast: correlation between mammographic and pathologic findings. *American Journal of Roentgenology*, **1994**, 162, 1307-11	5.4	103
57	Screening-detected and symptomatic ductal carcinoma in situ: mammographic features with pathologic correlation. *Radiology*, **1994**, 191, 237-40	20.5	39
56	Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy. *Breast Cancer Research and Treatment*, **1994**, 29, 117-25	4.4	165
55	Biological factors of prognostic significance in locally advanced breast cancer. *Breast Cancer Research and Treatment*, **1994**, 29, 259-64	4.4	22
54	Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. *International Journal of Cancer*, **1994**, 59, 619-28	7.5	180
53	Pathological prognostic factors in breast cancer. III. Vascular invasion: relationship with recurrence and survival in a large study with long-term follow-up. *Histopathology*, **1994**, 24, 41-7	7.3	234
52	The radiological appearances of invasive cribriform carcinoma of the breast. Nottingham Breast Team. *Clinical Radiology*, **1994**, 49, 693-5	2.9	29
51	Pathological-radiological correlations in benign lesions excised during a breast screening programme. *Clinical Radiology*, **1994**, 49, 853-6	2.9	28
50	Correlations between the mammographic features of ductal carcinoma in situ (DCIS) and C-erbB-2 oncogene expression. Nottingham Breast Team. *Clinical Radiology*, **1994**, 49, 559-62	2.9	32
49	Oestrogen receptor expression in ductal carcinoma in situ of the breast: relationship to flow cytometric analysis of DNA and expression of the c-erbB-2 oncoprotein. *British Journal of Cancer*, **1993**, 68, 156-61	8.7	66
48	Methodology of immunohistological detection of oestrogen receptor in human breast carcinoma in formalin-fixed, paraffin-embedded tissue: a comparison with frozen section methodology. *Histopathology*, **1993**, 23, 233-8	7.3	54
47	Precursor lesions of breast carcinoma. *Breast*, **1993**, 2, 220-223	3.6	6
46	Early experience in breast cancer screening: emphasis on development of protocols for triple assessment. *Breast*, **1993**, 2, 148-153	3.6	25
45	The mammographic appearances of fibromatosis of the breast. *Breast*, **1993**, 2, 175-179	3.6	5
44	Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long-term follow-up. *Histopathology*, **1992**, 20, 479-89	7.3	353

43	Tumour oestrogen receptor content allows selection of elderly patients with breast cancer for conservative tamoxifen treatment. *British Journal of Surgery*, **1992**, 79, 1314-6	5.3	19
42	Routine diagnosis of mammary Paget's disease. A modern approach. *American Journal of Surgical Pathology*, **1992**, 16, 58-61	6.7	31
41	P-glycoprotein expression in locally advanced breast cancer treated by neoadjuvant chemotherapy. *British Journal of Cancer*, **1992**, 66, 537-41	8.7	16
40	p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor. *British Journal of Cancer*, **1992**, 66, 583-8	8.7	88
39	The Nottingham Prognostic Index in primary breast cancer. *Breast Cancer Research and Treatment*, **1992**, 22, 207-19	4.4	792
38	Confirmation of a prognostic index for patients with metastatic breast cancer treated by endocrine therapy. *Breast Cancer Research and Treatment*, **1992**, 22, 221-7	4.4	43
37	Oestrogen receptor D5 antibody is an independent negative prognostic factor in gastric cancer. *British Journal of Surgery*, **1991**, 78, 334-6	5.3	42
36	A comparison of the clinical metastatic patterns of invasive lobular and ductal carcinomas of the breast. *British Journal of Cancer*, **1991**, 63, 634-5	8.7	66
35	The prognostic value of the monoclonal antibody (D5) detected protein, p29, in primary colorectal carcinoma. *British Journal of Cancer*, **1991**, 64, 379-80	8.7	
34	c-erbB-2 oncoprotein expression in primary and advanced breast cancer. *British Journal of Cancer*, **1991**, 63, 439-43	8.7	202
33	Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. *Histopathology*, **1991**, 19, 403-10	7.3	4492
32	Intracytoplasmic lumina--a useful diagnostic feature of adenocarcinomas. *Histopathology*, **1991**, 19, 83-7	7.3	17
31	A one year audit of fine needle aspiration cytology for the pre-operative diagnosis of breast disease. *Cytopathology*, **1991**, 2, 167-76	1.3	33
30	Nuclear and flow cytometric characteristics associated with overexpression of the c-erbB-2 oncoprotein in breast carcinoma. *Breast Cancer Research and Treatment*, **1991**, 20, 3-10	4.4	19
29	Suprahyoid Hodgkin's disease stage IA. *Radiotherapy and Oncology*, **1991**, 22, 190-4	5.3	4
28	Hormone sensitivity in breast cancer: influence of heterogeneity of oestrogen receptor expression and cell proliferation. *European Journal of Cancer & Clinical Oncology*, **1991**, 27, 908-13		58
27	Pathology and breast screening. *Histopathology*, **1990**, 16, 109-18	7.3	31
26	T-cell lymphoma associated with human immunodeficiency virus (HIV) infection. *Histopathology*, **1990**, 16, 189-91	7.3	8

25	Flow cytometric and histological analysis of ductal carcinoma in situ of the breast. *British Journal of Surgery*, **1990**, 77, 564-7	5.3	30
24	Cytological grading of breast carcinoma--a feasible proposition?. *Cytopathology*, **1990**, 1, 287-95	1.3	52
23	The relationship of "high risk" mammographic patterns to histological risk factors for development of cancer in the human breast. *British Journal of Radiology*, **1990**, 63, 845-9	3.4	23
22	Mammography in the pre-operative assessment and post-operative surveillance of patients treated by excision and radiotherapy for primary breast cancer. *Clinical Radiology*, **1990**, 41, 388-91	2.9	16
21	Correlation of morphology, immunophenotype, and flow cytometry with remission induction and survival in high grade non-Hodgkin's lymphoma. *Journal of Pathology*, **1989**, 158, 31-9	9.4	19
20	Polarized incident light microscopical enhancement of immunogold and immunogold-silver preparations: its role in immunohistology. *Journal of Pathology*, **1989**, 159, 13-6	9.4	10
19	An observation of DNA ploidy, histological grade, and immunoreactivity for tumour-related antigens in primary and metastatic breast carcinoma. *Journal of Pathology*, **1989**, 159, 129-34	9.4	21
18	An investigation of NCRC11 immunoreactivity in normal and neoplastic epithelia of the female genital tract and ovary. *Histopathology*, **1989**, 15, 187-94	7.3	
17	Ki67 immunostaining in primary breast cancer: pathological and clinical associations. *British Journal of Cancer*, **1989**, 59, 943-7	8.7	239
16	Invasive lobular carcinomas of the breast--the prognosis of histopathological subtypes. *British Journal of Cancer*, **1989**, 60, 605-9	8.7	89
15	c-myc oncogene product expression and prognosis in operable breast cancer. *British Journal of Cancer*, **1989**, 60, 669-72	8.7	32
14	Monoclonal antibody NCRC 11 reactivity with advanced breast carcinoma: lack of prognostic value. *Histopathology*, **1988**, 13, 695-7	7.3	5
13	Effect of LHRH agonist, Zoladex, on ovarian histology. *British Journal of Surgery*, **1988**, 75, 595-6	5.3	11
12	Microdochectomy for single-duct discharge from the nipple. *British Journal of Surgery*, **1988**, 75, 700-1	5.3	31
11	A new approach to the treatment of advanced high-grade non-Hodgkin's lymphoma--intensive two-phase chemotherapy. *Cancer Chemotherapy and Pharmacology*, **1988**, 22, 141-6	3.5	6
10	Immunocytochemical investigation of intermediate filament proteins and epithelial membrane antigen in spindle cell tumours of the breast. *Journal of Pathology*, **1988**, 154, 157-65	9.4	49
9	An investigation of optimal gold particle size for immunohistological immunogold and immunogold-silver staining to be viewed by polarized incident light (EPI polarization) microscopy. *Journal of Histochemistry and Cytochemistry*, **1988**, 36, 121-4	3.4	19
8	Tumour aneuploidy, prognostic parameters and survival in primary breast cancer. *British Journal of Cancer*, **1987**, 55, 449-54	8.7	70

7	Oestrogen receptors in primary and advanced breast cancer: an eight year review of 704 cases. *British Journal of Cancer*, **1987**, 55, 67-73	8.7	101
6	Helix pomatia and Ulex europeus lectin binding in human breast carcinoma. *Journal of Pathology*, **1987**, 152, 169-76	9.4	71
5	Evaluation of immunoreactivity with monoclonal antibody NCRC 11 in breast carcinoma. *British Journal of Cancer*, **1987**, 56, 295-9	8.7	41
4	Confirmation of a prognostic index in primary breast cancer. *British Journal of Cancer*, **1987**, 56, 489-92	8.7	258
3	A monoclonal antibody, NCRC-11, raised to human breast carcinoma. 1. Production and immunohistological characterization. *Histopathology*, **1984**, 8, 501-16	7.3	84
2	Immunohistochemical localization of Y hapten and the structurally related H type-2 blood-group antigen on large-bowel tumours and normal adult tissues. *International Journal of Cancer*, **1984**, 33, 727-36	7.5	67
1	Primary malignant mesenchymal tumour of the liver in an elderly female. *Histopathology*, **1983**, 7, 113-21	7.3	19